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Abstract
Heart transplantation is currently a viable option for the treatment of 
patients with end-stage cardiac disease. Although improved survival has been 
achieved over the last decade, transplant recipients remained vulnerable to the 
risks of rejection, infection, the effects of immunosuppression and accelerated 
transplant atherosclerosis.
Recent advances in molecular biology and recombinant DNA 
technology have fostered the concept of gene transfer. Successful gene transfer 
is dependant on the properties of vectors used in delivering genes to the target 
cells. The vectors used to date include adenovirus, retrovirus, adeno- 
associated virus and plasmid-liposome. Replication defective adenoviral 
vectors are currently the agents of choice for in vivo cardiovasculai' gene 
transfer because of their relative efficiency and ability in transducing non­
dividing cells. Disadvantages of adenoviral vectors include transient duration 
of transgene expression and potential cytotoxicity.
Gene transfer to the transplanted heart may represent a novel approach 
to the study of transplantation biology and may have therapeutic potential in 
the management of human transplantation disease. The availability of the 
donor heart at the time of harvest and the period of cold preservation may 
allow for a prolonged viral vector dwell time which would not be possible in in 
vivo vasculai* wall gene transfer. This prolonged dwell time may lead to
enhanced gene transfer in this setting. Also, the necessary use of 
immunosuppressive agents in transplant setting may modulate the potential 
cytotoxicity and duration of transgene expression of adenoviral-mediated gene 
transfer. In the cardiovascular system, nitric oxide (NO) derived from the 
vascular endothelium regulates vascular tone. Its other properties include 
inhibition of proliferation of smooth muscle cells, adhesion and activation of 
leukocytes and platelets. In addition, reduced bioactivity of nitric oxide is a 
feature of atherosclerosis and vascular- injury. Therefore, overexpression of 
nitric oxide may be beneficial in modifying accelerated transplant 
atherosclerosis.
The focus of this thesis was on adenoviral-mediated gene transfer in the 
heart transplant setting. It addressed the feasibility and favourable conditions 
to achieve efficient gene transfer in the donor heart during cold preservation. 
In particular, the effect of increased coronary distension during viral vector 
dwell and the potential role of warm ischaemia, during the transplant 
procedure, on efficiency of gene transfer were examined. Efficiency of gene 
transfer was assessed by histochemical staining of the reporter gene encoding 
for P“galactosidase. Further evaluation of the effect of temperature on gene
transfer by in vitro study was performed. The major limitation of adenoviral 
vectors, transient duration of transgene expression, was examined. The effect 
of immunosuppression on duration of transgene expression was assessed in 
both syngeneic and allogeneic transplantations. Transgene expression m 
transplanted hearts were assessed at 1, 4, 8 and 12 weeks. Finally, the
endothelial nitric oxide synthase gene was transferred into the donor hearts and 
the potential functional consequences studied.
The current study confirmed the feasibility of adenoviral-mediated gene 
transfer to the transplanted hearts. However, the efficiency of gene transfer 
was markedly affected by the conditions of gene deliveiy. The study in 
Chapter 3 demonstrated that coronary distension during the period of viral 
infusion could significantly improve gene transfer. This was further enhanced 
by allowing virus dwell during the period of warm ischaemia when 
transplantation was performed. Interestingly, virus dwell duiing the period of 
warm ischaemia alone did not improve gene transfer efficiency even though it 
was noted that gene transfer was somewhat more accentuated in subepicardial 
areas of organising ischaemia where rewarming occurs quicker. However, in 
vitro study of endothelial cells showed that gene transfer at 37^ C was 
significantly better than at 4°C or 10°C. Another major limitation of the 
adenoviral vector is the transient nature of transgene expression. This may 
pose a potential limitation to its effectiveness for clinical gene therapy. The 
need for immunosuppression in transplantation may modify this immune 
response and facilitate prolonged transgene expression. The study in Chapter 
5 showed that transgene expression persisted significantly longer in both the 
immunosuppressed syngeneic and allogeneic animals compared to the non- 
immunosuppressed animals. Therefore, ti’ansgene expression ushig adenoviral 
vectors is prolonged by immunosuppression in the heart transplantation 
setting. The concluding study confirmed that endothelial nitric oxide synthase
gene, a biologically active and relevant gene in the cardiovascular setting, can be 
successfully transferred into transplanted hearts by the methods defined 
earlier. However, overexpression of the recombinant protein in this model did 
not did not result in significant changes in functional myocai'dial activity and 
coronary perfusion. Whether the overexpression of eNOS may modify 
accelerated transplant atherosclerosis remains to be determined.
These findings may have important implications for the future 
development of adenoviral-mediated gene transfer in the heart transplant 
setting.
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Brief Histoiy of Heart Transplantation
In 1905, Carrel and Guthi'ie reported on a series of heterotopic heart 
and lung transplantations in dogs during the course of establishing the 
techniques for vascular surgery. This work was taken further by Mann and 
workers in the 1930s. In the mid-1940s in Russia, Demikhov performed a 
series of experiments showing the technical feasibility of intrathoracic 
heterotopic heart transplant and its ability to sustain circulation. However, it 
was not until the advent of cardiopulmonary bypass, when in 1960 saw the 
publication of Lower and Shumway’s classic paper^ in orthotopic cardiac 
transplantation, integrating advances in surgical techniques, recipient support, 
and donor heart preservation into a single approach. This established the basis 
for human heart transplantation.
In the field of early immunology, in the 1940s, the work of Medawar 
on skin grafts revolutionised the understanding of transplantation and the 
development of the concepts of immunology. Progress in laboratory research 
was translated into clinical reality when the first successful human orthotopic 
cai'diac transplantation was performed by Barnard in 1967 at Groote Schum* 
Hospital. This led to an increase in the number of cai’diac units world-wide 
undertaking this procedure. However, early results of heart transplantation 
were generally disappointing, and the procedure was largely abandoned by 
1970 with the notable exception of Stanford under the direction of Shumway.
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Through the 70’s and the 80s, progress achieved in laboratory and clinical 
research especially at Stanford resulted in improvement in the survival of heart 
transplant patients. Significant milestones contributing to the success include 
the use of surveillance endomyocardial biopsy^, improvement hi 
immunosuppressive agents especially cyclosporin A, and the diagnosis and 
management of rejection. Other important factors include advances in 
recipient and donor selections and the development of distant heart 
procurement programmes.
Challenges in Heart Transplantation
Heart transplantation is now a viable option for the treatment of end 
stage cardiac disease. Transplant recipients have approximately 80% survival 
at 1 year, with survival extending to 60% at 5 years^. Although improved 
survival has been achieved over the last decade, transplant recipients remained 
vulnerable to the risks of rejection"*’^ , infection and the effects of 
immunosuppression. In addition, long term survival is severely compromised 
by the condition of accelerated transplant atherosclerosis^. Further constraint 
to the widespread application of cardiac transplantation is the availability of 
donor organs.
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R ejection and Immunosuppression
Cardiac allograft rejection is a result of a complex immunological 
process involving the recognition of the allogeneic histocompatibility antigens 
of the grafted tissue by the host immune system. The most important 
histocompatibility antigens are those of the major histocompatibility complex 
(MHC), known in human as the HLA system. This distinguishes the "self 
from the "non-self and there is a high degree of polymorphism within the 
system. In addition, numerous other antigens of the minor incompatibility 
groups also contribute to the rejection process. The three main components of 
allograft rejection include donor specific T cytotoxic lymphocytes, non­
specific imflammatory cells and anti-donor antibodies. The main strategy for 
preventing and treating transplant organ rejection in clinical practice is the use 
of immunosuppressive agents. Other potential strategies for overcoming 
rejection are MHC-matching and the induction of tolerance. The application 
of MHC-matching is hampered by the high level of polymorphism in the genes 
encoding for HLA antigens and thus, the likelihood of a perfect match is 
remote. Also in clinical practice, this is further restricted by the ischaemic 
time constraint and the shortage of available donor organs. Transplantation 
tolerance refers to the elimination of the immune response to the antigens of 
the allograft while retaining the immune response to all other antigens in the 
environment. Presently, the induction of transplantation tolerance remains 
experimental in cardiac transplantation.
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All transplant recipients require indefinite immunosuppression to 
prevent rejection. Current immunosuppressive regimens are for most part 
immunologically non-specific in their mode of actions. Despite major 
improvements in immunosuppressive therapy, allograft rejection remains an 
important cause of morbidity and mortality in cardiac transplant recipients. 
New immunosuppressive strategy that specifically targets the transplanted 
heart may avoid the side effects seen in present immunosuppressive regimens. 
Gene transfer technology may potentially offer such a strategy.
Accelerated Transplant Atherosclerosis
Accelerated Transplant Atherosclerosis has emerged as the major cause 
of morbidity and mortality in long-term heart transplant recipients^’^ . The 
prevalence of this condition was found to be 3% at 1 year and 40% at 5 years 
in an angiographic s tu d y H o w ev e r ,  intravascular ultrasound imaging, a more 
sensitive method for detecting and quantitating intimai vascular wall 
thickening, highlighted the underestimation of the prevalence of this condition 
a n g i o g r a p h ic a l ly ^ T h e  predominant pathological findings are diffuse, 
concentric intimai thickening and perivascular inflammation involving large and 
medium-sized epicardial arteries to arterioles. The vascular’ lesion is 
characterised by marked proliferation of intimai smooth muscle cells with lipid 
accumulation and mononuclear cell infiltration. It differs from "native" 
coronary atherosclerosis in its generalised distribution throughout the coronary
18
vasculature and its rapid progression. Despite these differences, there aie 
morphological and functional similarities between accelerated transplant 
atherosclerosis and "native" atherosclerosis.
The pathogenesis of this condition remains the subject of intense 
debate. It is most likely to be multifactorial involving both immune and non- 
immune mechanisms. The common pathway to the development of this 
condition may be the "response to i n j u r y " I n  heart transplantation, the 
causes of endothelial injury include cold storage ischaemic injury, ischaemic- 
reperfusion injury, immune injury from acute and clironic rejections and viral 
infections^^. The biology of accelerated transplant atherosclerosis is still 
poorly understood and only considerable progress in its understanding may 
eventually lead to strategy in the treatment and prevention of this devastating 
condition. Currently, the only effective treatment is retransplantation.
Gene Transfer and Therapy
Since 1953 when Watson and Crick elucidated the structure of DNA, 
advances in molecular biology and recombinant DNA technology have 
cumulated in the potential use of gene transfer for the treatment of genetic and 
acquired diseases. Gene transfer is the introduction of recombinant DNA into 
the target cell. This can be divided into geim cell or somatic gene transfer.
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Early gene therapy concept involves the transfer, substitution or deletion of 
genes at germ cell level. The potential danger of mutagenesis and unpredictable 
results of germ cell manipulation with its ethical and biological consequences 
resulted in decreased interest of this technique for gene therapy. The main 
potential application of germ cell gene transfer is in the development of 
transgenic animals in the field of xenotransplantation. The main focus for gene 
transfer at present is into somatic cells. The ability to introduce therapeutic 
genes into target cells resulting in the expression of the genes and the 
production of the therapeutic proteins may have many beneficial clinical 
applications.
Somatic gene transfer can be carried out ex vivo or in vivo. In the 
former, the recombinant gene is transferred to the target cells in the laboratory 
after which they are returned into the host animal. In contrast, in vivo 
procedure involves the transfer of the recombinant gene into the host animal 
directly. Both techniques have applicability and the choice of the strategy 
depends on the target cells and the condition to be treated. Most of the human 
protocols on gene transfer to date used the ex vivo technique. The type of 
diseases and potential target cells or systems for gene therapy are diverse 
Successful gene therapy requires an efficient method of gene deliveiy that 
targets relevant cells and results in stable gene expression to acliieve 
therapeutic outcome without unnecessary deleterious side effects.
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Vector Systems
Early experiments with viruses and naked DNA complexed with 
calcium phosphate established the techniques for in vitro gene manipulation 
and genetic material transfer. The basis for gene therapy was then 
contemplated In the 1980s, the development of replication defective 
retroviral vectors and suitable packaging cell lines helped progress toward gene 
transfer experiments. The genetic transfer process is usually aided by the use 
of a vector system to deliver the recombinant gene into the intracellulai' site of 
the target cell for it to function appropriately. From an early stage, it was 
realised that successful gene therapy is dependant on efficient methods of gene 
delivery. The vector systems to date can be broadly divided into non-viral and 
viral vector systems (Figure 1.1). Non-viral vectors include naked DNA, 
liposome and methods incorporating receptor-mediated endocytosis. Viral 
vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, 
HIV/Lentivirus and Sendai virus/HJV.
The ideal vector system for gene transfer should: a) have no insert 
DNA size constraint, b) target either entry into specific cells or limits 
expression to target cells, c) not evoke an immune response, safe for the 
recipient and environment, d) be stable and free from insertional mutagenesis, 
e) be easily produced and in high titre/concentration and f) be possible to 
regulate the level of transgene expression. At present no such vector system 
exists. Currently, cationic liposomes and viral vectors are the most commonly
21
used agents in the field of cardiovascular gene transfer. The advantages and 
disadvantages of these vectors will be considered.
Non-viral Vectors
Liposome-Mediated Gene Transfer
Liposomes are self-assembling colloidal particles in which a lipid 
bilayer encapsulates a fraction of the surrounding aqueous medium. Cationic 
liposomes are positively charged lipid vesicles that incorporate negative 
charged recombinant DNA and facilitate the delivery of the DNA into the 
target cells (cell membrane being negatively charged) through fusion with the 
cell membrane or receptor-mediated endocytosis. Delivery of liposomes is 
non-specific as there are no specific receptors involved in binding and entry of 
these complexes into target cells. In addition to vascular wall gene transfer^^’^ ,^ 
cationic liposomes have been used to deliver genes in vivo to lung epithelial 
cells porcine arteries and brain tissue and the systemic circulation. The 
principal disadvantages of liposome-mediated gene transfer are poor 
transduction efficiency and transient gene expression. Potential advantages of 
this system include the fact that liposomal-mediated DNA remains episomal in 
the nucleus, thus avoiding problems of random insertional mutagenesis. 
Liposomal vectors, with no viral sequences, have lower immunogenicity and 
there is no cDNA size constraint in vector construction. Liposomal vectors 
have been shown to have very good biosafety profile With
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improvements in formulation resulting in greater efficiency of gene transfer, 
this vector system holds great potential for the future
Receptor-Mediated Endocytosis
Gene tiansfer is achieved by conjugating the recombinant DNA with a 
cell-specific carrier molecule which acts as a ligand for the target cell receptor 
The advantage of this method is the potential for targeting gene transfer to 
specific receptors expressed by the cells of interest. The hepatocyte-specific 
asialoglycoprotein receptor has been targeted by an electrostatic complex, 
asialorosmucoid-polylysine conjugated to the DNA of interest in gene 
transfer to the liver. Another example is the transferrin-polylysine/DNA 
conjugate which binds to transferrin receptors The efficiency of this 
system is enhanced by the addition of substances, such as chloroquine, which 
disrupt the endosome/lysosome pathway facilitating the delivery of DNA into 
the nucleus. Simultaneous addition of replication defective adenoviral vectors 
is another method to disrupt the endosome/lysosome pathway and increase 
the efficiency of gene transfer with this method.
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Viral Vectors
Retrovirus
Retroviruses were the first viral vectors used in human gene therapy 
Retroviruses are RNA viruses which have the capacity to convert RNA to 
DNA by a vhal enzyme, reverse transcriptase. It comprises an inner core 
which include the RNA, virally coded protease, reverse transcriptase and 
integrase enzymes enclosed by a phospholipid envelope. The virus infects 
cells by specific binding of an envelope protein to a cell surface receptor. The 
RNA is then ti'ansferred to the nucleus and during this process RNA is 
converted to double stranded DNA by reverse transcriptase. The double 
stranded DNA is integrated into the host cell chromosome, a process mediated 
by the enzyme integrase The integrated viral DNA is termed the provirus 
and functions like an independent gene. The integration is a semi-random 
process with multiple sites used although some are used more frequently than 
others RNA is transcribed from the integrated provirus and translated to 
make viral proteins. These proteins combine with full length RNA to form 
new viral particles.
The most commonly used retrovirus in gene transfer experiments is the 
Moloney mui'ine leukaemia virus. Retroviral-mediated gene transfer has been 
used successfully in the ex vivo setting which involves the removal of
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relevant target cells from the host and transfecting them in vitro before 
returning the modified cells back to the host.
However, the major limitation of the retroviral vector for in vivo gene 
transfer is its inability to transduce non-replicative cells. Replication of target 
cells is required for pro viral integration Cells of the arterial wall and 
cardiomyocytes are usually quiescent and therefore gene transfer using 
retroviral vectors is inefficient. As retroviral RNA is stably integrated into the 
host cell chromosome, random insertional mutagenesis is a concern. Other 
disadvantages include the inability to grow the virus to high titre, instability 
from handling and rapid inactivation in primate serum This may limit its
use in large animals or human applications. Direct in vivo gene transfer into 
vascular cells with retroviral vectors has also been attempted with transduction 
efficiencies even lower than those found in vitro However, a major
advantage of retrovirus-mediated gene transfer is prolonged transgene 
expression as a result of integration of the pro virus into the host cell 
chromosome.
Interestingly, a lentiviral vector system based on human 
immunodeficiency virus had been developed which successfully transduced 
non-dividing cells Lentiviruses, unlike most retroviruses, can transduce 
non-replicative cells and the transferred genes are integrated into the host cell 
chromosome which is a desirable feature for long-term gene expression. 
Therefore, this retroviral vector overcomes the primary disadvantage of other 
retroviral vectors which is the inability to transduce quiescent cells while
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retaining the integration benefit. However, currently there are considerable 
biosafety implications from using lentivirus vectors which may restrict their 
use in human gene therapy.
Adeno-associated Virus (AAV)
Adeno-associated virus is a member of the parvovirus family. The 
AAV genome is a single-stranded linear DNA molecule with terminal repeats 
at both ends which fold into hairpin structures and function as origins of 
replication AAV depends on the co-infection of a helper-virus, either an 
adenovirus or herpesvirus for efficient replication. One potential advantage of 
AAV is that it preferentially integrates into chromosome 19. Other important 
features are a) its ability to infect a wide variety of mammalian cells, b) 
ability to transduce non-dividing cells, c) stable and replicates to high titre. 
Disadvantages of AAV include the absence of a system of growing high titre 
AAV stock. Secondly, the procedure for growing AAV recombinants is 
cumbersome. The growth of a recombinant stock requires the presence of both 
AAV and helper virus genes and therefore the resulting recombinant is 
contaminated by wild type adenovirus and sometimes wild type AAV 
particles. Further modifications of this vector system may overcome these 
disadvantages and provide a promising vector for future gene therapy.
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Sendai virus-DNA-Liposome Complexes
In this method, inactivated Sendai virus (hemagglutinating virus of 
Japan), and the nuclear protein, high-mobility group 1 (HMGl) are complexed 
with liposomal DNA to achieve efficient gene transfer. The HVJ facilitates 
membrane fusion at the cell surface at neutral pH and facilitates the 
introduction of DNA directly into the cell cytoplasm, avoiding lysosomal 
degradation The HMGl nuclear protein increases the efficiency of nucleai* 
translocation and expression of the DNA This system has been used 
successfully to introduce and express the human insulin gene and the human 
renin gene in adult rat liver This system has also been used to transfer 
genes to the rat carotid artery in vivo and the myocardium efficiently. 
Limitations to this system include transient nature of gene expression and the 
technical expertise required in the preparation of the complex prior to 
transduction. In addition, the experiences on this vector system have been 
restricted to a few laboratories.
Adenovirus Vectors
Adenoviruses are intermediate-sized DNA viruses with genomes 
consisting of linear double-stranded DNA molecules of 32,000 to 36,000 base- 
pairs. The virion is about 70nm in diameter, consisting exclusively of protein 
and DNA. The DNA is contained within an icosahedral protein coat or 
capsid. Protruding fi-om each of the twelve vertices of the capsid is a fibre
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protein which plays an important role in the successful transfection of target 
cells.
The genome of the adenovirus is divided into two major non­
contiguous overlapping regions, early and late, based on the time of 
transcription after infection. The distinct early regions are E la, Elb, E2a, E2b, 
E3 and E4. There is also a late region under the control of the major late 
promoter. In general, the early genes are involved in the regulation of viral 
transcription, transformation and DNA replication while the late genes code 
for viral structural proteins. The adenoviral vectors used to date have the El 
region deleted to prevent them from replicating in target cells (Figure 1.2). 
However, these vectors could be propagated in the laboratory in 293 cells (a 
cell line that is transformed by adenovirus 5 DNA and expresses the El 
genome thereby providing proteins in trans) The successful transduction of 
target cells by adenoviral vectors requires three distinct, sequential steps; 1) 
attachment of the virus to specific receptors on the surface of the target cell; 
2) internalisation of the virus; and 3) transfer of viral genome to the nucleus 
where it can be expressed (Figure 1.3).
Replication defective adenovirus vectors are currently the agents of 
choice for in vivo cardiovascular gene transfer More efficient gene transfer 
is observed using these agents than any other to date. A major advantage of 
adenovirus vectors is the ability to transduce non-replicative cells They can 
be grown to high titre and are not incorporated into the host cell genome but 
remain episomal. Random insertional mutagenesis is therefore not a major
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concern. However, as chromosomal integration does not occur, the duration of 
expression of the transgene is limited. Furthermore, systemic administration 
of adenovirus cannot be repeated due to the presence of host immune 
responses. Disadvantages of adenoviral mediated gene transfer therefore 
include potential cytotoxicity, limited duration of gene expression, and the 
inability to administer a second dose due to immune responses
Despite the drawbacks outlined above, adenovirus vectors have had 
many applications to date. They have been used to transfer the cystic fibrosis 
transmembrane conductance regulator gene to the bronchial epithelium of 
cottontail rats the nasal epithelia of patients with cystic fibrosis and the 
biliary tract of rats. These vectors have also been used to transfer the gene for 
the low density lipoprotein receptor to both normal and low density 
lipoprotein receptor knockout mice and Watanabe heritable hyperlipidémie 
rabbits Adenoviral vectors have also been used to transfer genes to skeletal 
muscle, ventricular myocytes, human blood monocyte derived macrophages, 
mouse and human hepatocytes, rabbit synovium, and neurones and glia in the 
brain Recently, adenoviral vectors have been used to transduce vasculai’ 
wall cells'^ ’^'*^ . Adenoviral-mediated transfer of a  1-antitrypsin cDNA to 
human endothelial cells in vitro was described by Lemarchand et al 
Adenoviral vectors have also been used to transfer the genes for (3-
galactosidase and CFTR to the carotid artery and jugular vein of sheep in vivo. 
In addition, adenoviral vectors have been used to transfer genes into the heart
50,51
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Gene Transfer and the Heart
The expression of recombinant genes in the human coronary system 
and myocardium holds promise for the treatment of a number of inherited and 
acquired cardiovascular diseases.
Wolff et al first described the feasibility of in vivo gene transfer to 
muscle cells by direct injection of naked DNA plasmid. In this series of 
experiments although gene transfer was successful, the efficiency was 
extiemely low at about 1% of all cells. This raised the question of whether 
cardiac cells could be similarly transduced. This was addressed by Lin and 
Acsadi who in separate experiments, reported successful gene transfer into 
cardiac cells by direct in vivo injection of naked plasmid DNA. Again the level 
of transgene expression was low and successful gene transfer was restricted 
mainly to the site of injection. Although multiple injections into the heart is 
possible, the level of transgene expression may still be limited and the 
potential for myocardial damage resulting from such a manoeuvre would be 
undesirable. Despite the low level of gene transfer by this method, this does 
not exclude the possibility that isolated application might be developed. For 
example, the direct injection of a plasmid encoding the gene for a potent 
secreted mitogen such as VEGF^^ (vascular- endothelial growth factor), where 
only a small amount of recombinant protein is required to exert an effect, might
30
stimulate collateral formation in ischaemic areas of the myocardium. Another 
interesting issue raised by these studies was the duration of ti-ansgene 
expression. Acsadi et al showed the loss of transgene expression in the heart 
of normal rats after only 28 days. But when these rats were treated with 
cyclosporine, transgene expression was stable to 60 days. Also, when the 
injection was done in nude rats, the duiation of transgene expression was 
significantly prolonged. These early observations suggested the role of the 
immune system in the stability of transgene expression.
Since these early experiments, alternative approaches and vector 
systems have been developed and used to achieve better efficiency of gene 
transfer. These include the use of adenoviral, adeno-associated viral, HVJ- 
liposomal and cationic liposomal vectors. Retroviral vectors had been 
universally inefficient due to the quiescent nature of endothelial cells and 
cardiomyocytes. However, Nabel and workers were successful in using this 
vector in transducing vessels following injury This was probably related to 
cellular proliferation following injury to the vessels studied.
Adenoviral vectors have been used increasingly in cardiovascular gene 
transfer because of their relative efficiency in transducing a wide variety of 
cells Stratford-Perricaudet et al utilised a replication-defective
recombinant adenovirus encoding for the reporter gene, p-galactosidase, for 
studying the specificity, efficiency and stability of transgene expression in the 
heart following intravascular administration of the vector into a neonatal mice. 
Transgene expression was seen in the liver, intestine, lung, skeletal muscle and
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heart. Only approximately 0.2% of cardiac cells were found to stain positive 
for the reporter gene. However, he found that transgene expression persisted 
for up to a year albeit in decreasing amount. When the experiment was 
repeated in adult mice, efficiency was reduced and duration of transgene 
expression was greatly shortened. Another point highlighted in the study was 
that ineffectiveness of intravenous injection in targeting the heart for gene 
transfer. Coronary arteries present a more challenging target for gene transfer 
compared to peripheral arteries due to access and the critical importance of 
maintaining distal perfusion. Nabel et aP^ used a double-balloon catheter for 
site specific gene transfer to peripheral vessels successfully. Access to the 
coronaiy ai’teries for the purpose of gene transfer might be possible with minor 
modifications to standard catheterisation and angioplasty techniques. 
Chapman et al^  ^used a modified percutaneous perfusion balloon catheter to 
deliver a reporter gene in liposome into coronary arteries of dogs. The 
efficiency of gene transfer was hampered by the vector system used. The 
potential for this technique was supported by French et al who successfully 
transduced coronary arteries of pigs using a similai' catheter. The study 
demonstrated that adenoviral vector was significantly more effective in 
achieving gene transfer than liposomal system. Despite this, the absolute level 
of recombinant protein per target segment was still relatively low and the 
overall level of gene transfer was low. In contrast, Leiden and colleagues 
achieved efficient level of gene transfer to the whole heart by infusing a 
replicative-defective recombinant adenovirus into the coronary arteries of
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rabbits using a percutaneous angiographic catheter system*"^ Animals were 
sacrificed 5 days to 2 months following virus infusion and the myocardium 
analysed histochemically for transgene expression. Cardiomyocytes, 
fibroblasts, endothelial cells and smooth muscle cells were successfully 
transduced. All areas of the heart including atria and ventricles showed gene 
expression. Efficiency of gene transfer was high. However, the transgene 
expression had mostly disappeared after 1 month following virus infusion. 
Another interesting finding was the absence of inflammatory response or 
myocardial necrosis. This is important because of the question of vector- 
induced toxicity.
These studies demonstrated the feasibility of gene transfer to the 
myocardium with an adenoviral vector via the intravascular route. These 
observations were supported by other studies using adenoviral vectors for 
gene transfer into the myocardium The route of adenoviral vector
administration in these studies was mainly by direct injection into the 
myocardium. Although this was a much more invasive technique, specific area 
of the myocardium could be targeted. In one study an area of myocardial 
infarction was targeted by direct injection with the recombinant adenovhal 
vector. It showed a lower level of gene transfer in the peri-infarcted area 
compared to normal myocardium. In addition, most of these direct injections 
into the myocardium using the adenoviral vectors showed inflammatory 
responses particularly along the needle tract The inflammatory responses
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were probably due to both the vectors and the traumatic effect of the needle. 
This may limit the technique for future gene therapy.
Gene Transfer in the Transplanted Heart
Despite the success of allograft heart transplantation in recent years 
complications including rejection, toxic effects of immunosuppression and 
accelerated transplant atherosclerosis continue to be major problems. Gene 
transfer may offer a new strategy for studying these processes and may offer a 
potential strategy for adverting them. Heart transplantation may be ideally 
suited for gene therapy as explanted donor hearts are commonly maintained in 
preservation solution for up to 6 hours. During this period, the organ would 
be an ideal substrate for gene therapy. Defined doses of gene therapy can be 
applied under controlled conditions of temperature, pressure and 
concentration.
The first published study looking into gene transfer in the transplanted 
heart was reported by Wang et al In this study, plasmid DNA encoding 
reporter genes was injected directly into the myocardium of heterotopically 
transplanted hearts following reperfusion. The hearts were harvested at 
different time points for assessment of gene transfer. Gene transfer was 
demonstrated for up to 60 days. The weakness in this study was the lack of 
controls and quantification of gene transfer was by lumiminscence
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measurement of luciferase activity. Therefore, it was difficult to assess the 
efficiency of gene transfer as luciferase is a very sensitive marker and 
endogenous luciferase in rat hearts may distort the results. Although p-
galactosidase, as a reporter gene, was also used, the distribution of transgene 
expression was not clarified in this study.
Access to the donor heart from the time of harvest to the time of 
implantation may provide a unique opportunity for a prolonged exposuie of 
the transducing vector to the heart. Ardehali et al utilised this advantage 
using a cationic liposomal vector carrying the reporter gene luciferase in 
transducing donor hearts at the time of harvest. He injected the vector into the 
heart via three routes a) apex of the heart, b) right atrium and c) the coronary 
arteries. The vector was not flushed out of the donor hearts before 
transplantation. The apical injection revealed transgene expression restricted 
at the injection site. In the right atrium group, transgene expression was 
detected mainly in the right ventricle. But in the group that had the vector 
injected into the coronary arteries, transgene expression was present in both 
ventricles and also the coronary arteries. This study did not indicate the 
efficiency of gene transfer. Immunostaining for luciferase was not helpful in 
clearly identifying the cell types transduced. However, this study did support 
the feasibility of gene transfer to the transplanted heart and indicated that the 
intracoronary route may be ideal for widespread distribution. Efficiency may 
be improved with another vector system.
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Sawa et al used the HVJ liposome vector carrying either FITC- 
labelled oligonucleotide or p-galactosidase successfully in ti’ansducing donor
hearts via the coronary arteries at the time of harvest in a rat model. The dwell 
time of the vector was about 32 minutes. Transgene expression assessed 3 
days later showed all layers of the myocardium transduced with the reporter 
genes. There was no signs of toxicity. But no quantifiable value was given for 
the efficiency of gene transfer. The same group reported on a comparative 
study between HVJ liposome and cationic liposome vectors which showed 
that the efficiency was seven times higher using the HVJ liposome vector.
In this study, the group also transduced donor hearts with the HVJ liposome 
vector carrying the manganese-superoxide dismutase gene (SOD) which 
resulted in better tolerance to ischaemic-reperfusion injury. Fyfe et al was 
able to transfer the HLA-B7 (MHC class 1) gene into donor hearts using 
cationic liposome in a mouse syngeneic heart transplantation model. This 
showed marked evidence of rejection in the HLA-B7 transduced hearts 
compared to control even though the level of gene transfer was extremely low. 
However, the importance of this study related to the feasibility of transferring 
immunologically relevant and important genes in the transplantation setting.
Lee et al using an adenoviral vector carrying the reporter gene, P- 
galactosidase, studied the duration of transgene expression in a mouse 
heterotopic heart transplant model. All donor hearts were stored at 4 C for 
15 minutes after viral infusion into the coronary arteries prior to 
transplantation. Results were quantified by counting the number of
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transduced cells per mid ventricular section stained histochemically. All cell 
types were transduced but predominantly cardiomyocytes. Transgene 
expression decreased with time but this was still present at 30 days after gene 
transfer. No toxicity was reported. Only one concentration of viral solution 
was used. The effect of higher and lower concentrations of virus was not 
addressed in this study.
Many of the basic issues of gene transfer using the adenoviral vector in 
the heart transplant setting remained unanswered. The optimal doses of virus 
and the conditions favourable to adenoviral-mediated gene transfer in the 
transplant setting have not been fully addressed.
Adenoviral Vector and the Immune System
One of the major limitation of adenoviral vectors is the transient nature 
of transgene expression. This has been consistently shown in a number of 
studies in different animals'^^’^'*^’^ '^^ *^ . However, transgene expression was 
prolonged in nude and new-born animals suggesting an immunological basis. A 
fundamental problem with first generation recombinant adenoviral vectors is 
that deletion of E l sequences is insufficient to completely ablate expression of 
other early and late viral genes or to completely prevent replication of viral 
DNA The immune response may be directed against the vector, the 
transgene product or the leaky viral proteins. Another reason for the loss of
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gene expression may be due to the episomal nature of the viral DNA in the 
transduced cells leading to DNA disintegration. In addition, both the cellular 
and humoral immune response have been implicated in the loss of transgene 
expression using adenoviral vectors Also, the humoral response may be 
responsible for the ineffectiveness of gene transfer following readministration 
of the adenoviral vector The use of immunosuppressive agents following 
adenoviral-mediated gene transfer into muscle cells had resulted in prolongation 
of transgene expression Due to the toxic side effects of immunosuppressive 
agents, the routine use of these agents may not be desirable. In clinical heart 
transplant, immunosuppressive agents are routinely used to prevent and treat 
allograft rejection. However, little is know of the effects of the necessary use 
of immunosuppression in the allograft heart transplant setting on transgene 
expression. This warrants further investigation.
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General Aims
1. Validation of animal model of heterotopic heart transplantation.
2. Experiments to define conditions for efficient adenoviral-mediated gene
transfer.
3 Experiments to study the duration of transgene expression in the
syngeneic and allogeneic heart transplant setting.
4. Experiments to study the feasibility and effects of transferring a
biologically relevant gene, the endothelial nitric oxide synthase (eNOS) 
gene, in the heart transplant setting.
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Liposomes Viral vectors
DNA
alone
b Plasmid/ viral particles
Figure 1.1: Gene transfer vectors
Diagram depicting non-viral and viral vectors used in gene transfer
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Figure 1,2; Adenovirus genome
Adenovirus genome showing the early and late transcription regions. 
First generation adenoviral vectors had the E l region deleted making them 
replication defective.
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Adenovirus Vector Design, Production, 
and Gene Transfer
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Figure 1.3: Adenoviral vector system
Adenovirus vector design, production and mechanism of gene transfer.
42
Chapter 2 : Design Of Experiments And
Methods
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Specific Aims of Study
The aim of this research was to exarrdrie the use of adenoviral vectors 
for gene transfer in the setting of heart transplantation. Access to the donor 
heart at the time of harvest provides a unique opportunity for genetic 
manipulation of this organ. Specifically, this study addressed the feasibility of 
gene transfer to the donor heart, the duration of transgene expression after 
transplantation and the feasibility of overexpressing a biologically relevant 
gene product, endothelial nitric oxide synthase (eNOS) in the transplanted 
heart.
Specific Aim 1: Hypothesis: Adenoviral-mediated gene transfer can be 
used to genetically modify the donor heart.
The aim of this section was to determine the optimal conditions for 
gene transfer to the donor heart. We first examined a dose response curve for 
adenoviral-mediated gene transfer at 4 C (A below) and then studied the 
effect of varying the conditions of exposure to the adenoviral vector (B below). 
Heterotopic syngeneic transplants between Lewis rats were used in these 
experiments.
A) In this section, the optimal dose of virus for gene transfer at 4”C
7 8were studied. The following concentrations of virus were used; 10 ,1 0  , and
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10^ plaque forming unit per ml (pfu/ml). Donor hearts were transduced with 
each of these concentrations of virus for 1 hour at 4°C. These donor hearts 
were then transplanted into recipient animals. Four days after
transplantation, the animals were sacrificed, the transplanted and recipient 
native hearts were harvested and analysed for transgene expression. Sham 
transduced syngeneic transplants were used as controls.
B) In this section the effect of varying conditions of adenovirus 
delivery on transgene expression were assessed. At the time of donor heart 
harvest, gene transfer, using the optimal concentration as determined by the 
experiments in section (A), in varying conditions were examined. Four days 
after transplantation, the animals were sacrificed, the transplanted and 
recipient native hearts assessed for transgene expression.
Specific Aim 2: Hypothesis: Temperature affects efficiency of
gene transfer.
The aim of this section was to determine the effect of temperature on 
the efficiency of gene transfer in endothelial cells. In vitro experiments were 
devised in which human umbilical vein endothelial (HUVEC) cells were 
transduced with an adenoviral vector encoding for the p-galactosidase gene 
(AdLacZ) at 4°C, 10°C and 37"C.
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Specific Aim 3: Hypothesis: Prolonged transgene expression in the 
transplanted heart may be possible after ex vivo adenoviral-mediated 
gene transfer.
The aim of this section was to examine the duration of transgene 
expression in the transplanted heart having determined the optimal dose and 
conditions in Specific Aim 1. We examined the duration of transgene 
expression following a) syngeneic transplantation in non-immunosuppressed 
animals (A below), b) syngeneic transplantation in immunosuppressed animals 
(B below), and then c) allogeneic transplantation in immunosuppressed 
animals (C below) (Donors - Brown Norway; recipients - Lewis rats).
A) To determine the duration of transgene expression in non- 
immunosuppressed syngeneic animals, donor hearts were transduced at the 
time of harvest by a dose of AdLacZ ( in conditions determined by Specific 
Aim 1) and then transplanted into syngeneic recipients. After transplantation, 
animals were harvested at the following time points: 1, 4, 8, and 12 weeks. Six 
animals were used for each time point. Transplanted hearts were harvested at 
these timepoints and analysed for transgene expression.
B) To determine the duration of transgene expression in 
immunosuppressed syngeneic animals, donor hearts were transduced at the 
time of harvest by a dose of AdLacZ (in conditions determined by Specific 
Aim 1) and then transplanted into syngeneic recipients. After transplantation, 
animals were treated with cyclosporine by orogastric injection, 10 mg per 1% 
each day for 14 days followed by 5 mg per kg per day thereafter^^’^ .^ Animals
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were sacrificed at the same time points as described in part A above. 
Transplanted hearts were analysed for transgene expression.
C) To determine the duration of transgene expression in 
immunosuppressed allogeneic animals, donor hearts (from Brown Norway 
rats) were transduced at the time of harvest by a dose of AdLacZ (in 
conditions determined by Specific Aim 1) and then transplanted into allogeneic 
recipients (Lewis rats). After transplantation, animals were treated with 
cyclosporine by orogastric injection, 10 mg per kg each day for 14 days 
followed by 5 mg per kg per day thereafter by orogastric injection. Animals 
were sacrificed at the same time points as described in part A above. 
Transplanted hearts were analysed for transgene expression.
Specific Aim 4: Hypothesis: Nitric oxide synthase (NOS) can be
overexpressed in the transplanted heart using adenoviral-mediated 
gene transfer.
The aim of this section was to study the feasibility o f transferring 
biologically relevant genes to the donor heart. Two groups of heterotopic 
syngeneic transplants between Lewis rats were used in the experiments.
Using the optimal dose and conditions as determined by Specific Aim 
1, twelve rat heart transplantations were carried out in each group. Group 1 
received an adenoviral vector encoding for the bovine endothelial nitric oxide 
synthase gene (AdeNOS) and Group 2 received AdLacZ as controls. The
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transduced hearts were transplanted into recipient animals. These animals 
were sacrificed 4 days later. Successful gene transfer and transcription were 
assessed by the detection of DNA and mRNA of the transgene by polymerase 
chain reaction (PCR) and reverse transcriptase-polymerase chain reaction (RT- 
PCR) respectively. The 5' probe used in these analysis included viral 
sequences that would allow differentiation between endogenous eNOS and 
transgene expression of eNOS. Transgene expression at protein level was 
detected by immunohistochemical staining. Antibodies to endothelial bovine 
NOS were used which did not cross react with the inducible isoform of NOS. 
Activity and functional assessment of recombinant eNOS were made using an 
activity assay and isolated heart preparation respectively.
Adenoviral Vectors
Generation, Propagation and Purification of Adenoviral Vectors:
An adenoviral vector encoding for the P-galactosidase gene (AdLacZ) 
under the control of the Cytomegalovirus (CMV) promoter was provided by 
Dr J M Wilson from the Institute of Gene Therapy, University of 
Pennsylvania. This vector had been used by the present laboratory to 
transduce a number of cell lines in vitro and the rabbit carotid artery in vivo 
with high efficiency. Cells transduced with this vector stained blue when
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exposed to X-Gal chromogen. This allowed the efficiency of gene transfer to 
be assessed. This vector was used in all the studies described in Speeific Aims 
1 ,2 ,3  and 4 of this thesis.
An adenoviral vector expressing the bovine endothelial nitric oxide 
synthase (AdeNOS) gene was generated by Dr O'Brien (Mayo Clinic). The 
cDNA for eNOS was cloned into a subsegment of the adenoviral genome 
which was itself cloned into a plasmid. The eNOS gene in this case was under 
the control of the CMV promoter. The resulting construct was cotransfected 
with dl309 (adenoviral DNA) into 293 cells. Recombinant adenovirus was 
generated as a result of homologous recombination. Viral plaques were 
selected and propagated in 293 cells. Viral DNA was enriched by Hirt 
extraction and screened by restriction mapping and polymerase chain reaction 
for the presence of eNOS DNA. Viral preparations were generated by 
infecting confluent monolayers of 293 cells with viral stock at an MO I 
(multiplicity of infection ) of 10 pfu/cell. Virus was purified by double cesium 
chloride gradient ultracentrifugation and dialyzed against 10 mmol/L Tris, 1.0 
mmol/L MgClz, 1.0 mmol/L HEPES, and 10% glycerol for 4 horns at 4^C. 
Viral titre was determined by plaque assay. eNOS activity was confirmed by 
positive NADPH diaphorase staining in confluent 293 cells transduced with 
AdeNOS. This vector has been used successfully to transduce porcine 
coronaiy smooth muscle cells in vitro. The functional nature of the transgene 
was demonstrated by increased production of nitrite and cyclic GMP levels by
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cells transduced with AdeNOS in comparison to cells transduced with 
AdLacZ.
Adenoviral vectors used were replication incompetent due to El a 
deletion. However, cell lines containing this region of the adenovirus genome 
could complement Ela-deleted virus and support productive infection. The 
human 293 cell line was derived for this purpose by the introduction of 
sheared fragments of Adenovirus 5 (Ad5) DNA into an embryonic kidney 
carcinoma cell line This cell line contains the El region of the adenoviral 
genome and can therefore provide protein products in trans, thus allowing for 
the propagation of replication defective adenoviral vectors.
During the propagation of the adenoviral vector, replication competent 
virus may be generated. Therefore in order to exclude wild-type 
contamination, the defectiveness of the AdeNOS for replication was tested by 
adding the virus ( lO^pfu/ml) to a monolayer of diploid human embryonic lung 
fibroblasts (60 mm dish). Replication competent viruses at an MOI of > 10 
produce a cytopathic effect and destroy the monolayer in < 3 days. Infection 
with the AdeNOS at a comparable MOI produced no observable cytopathic 
effect after 5 days. This showed the replication defectiveness of the vector. 
Furthermore, polymerase chain reaction for detecting El A was performed on 
all the adenoviral vector preparations. This was negative in all the adenoviral 
vector preparations tested but was positive in dl309 which was used as a 
positive control. Both methods described excluded wild-type contamination 
of the adenoviral vectors. Wild-type contamination of recombinant adenoviral
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vectors may lead to confounding factors which may affect laboratory 
experiments. In addition, it may have biosafety implications in both 
laboratory and clinical settings.
The adenoviral vectors were stored at -70^C in 0.0IM Tris, 0.0IM 
MgCl, and 10% glycerol. For use in experiments, the viral solution was 
thawed and diluted in 2% fetal calf serum in 199 medium to the required 
concentrations. It was noted that repeated thawing and freezing of the viral 
solution led to reduced infectivity of the vector.
Heterotopic Abdominal Heart Transplantation in a Rat 
Model
Animals
Lewis rats (Rtl^) were used as donors and recipients for syngeneic 
transplants. This combination did not result in rejection of the transplanted 
organs. For allogeneic transplants, Brown Norway (Rtl") rats were used as 
donors and Lewis rats as recipients. The Brown-Norway to Lewis strains 
combination represented a severe immunological mismatch and donor hearts 
were normally rejected in approximately seven days^^.
All animals received humane care in compliance with the “Principles of 
Laboratoiy Animal Care” formulated by the National Society for Medical
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Research and the “Guide for the Care and Use of Laboratory Animals” 
prepared by the Institute of Laboratory Animal Resources and published by 
the National Institutes of Health (NIH Publication No. 86-23, revised 1985).
Heterotopic Heart Transplantation
Rat heterotopic abdominal heart transplantation is a well established 
animal model in transplantation research. Heterotopic abdominal heart 
transplantation has been used extensively as a convenient and reproducible 
technique to study many aspects of the host immunological responses to 
allograft tissues. It is technically uncomplicated and has the advantage of 
easily determining graft function by palpation of the beating heart. However, 
as the left ventricle is not loaded in this model, ftmctional studies and results 
should be interpreted with caution. Although functional impairment of the left 
ventricle has been shown at 1 week after transplantation, for immunological 
and gene transfer research, heterotopic abdominal heart transplantation remains 
a valuable model that is widely used. This model proves to be effective, cost 
and time efficient because the surgical procedure is simple, relatively fast and 
technically successful. With practice, appropriate microsurgical skills and 
equipment, success approaches 95%. It was for these reasons that this 
research protocol adopted this animal transplantation model.
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Preliminary Training in Microsurgery
The applicant's initial exposure to microsurgery was in the Mayo 
Microvascular Training course. Instructions were given concerning the care 
and use of the operating microscope and standard microsurgical 
instrumentation. Specifically, the training was in the techniques of arterial to 
arterial, venous to venous and arterial to venous anastomosis of femoral 
vessels in rats.
Following this, the training protocol for heterotopic abdominal heart 
transplantation in the rat model was approved, where the necessary skills for 
performing the operation with low mortality were acquired.
Techniques of Heart Transplantation and Gene Transfer: 
Donor: Anaesthesia and operation
The donor animal was anaesthetised with an intraperitoneal injection of 
5 mg sodium per 100 gm body weight of pentobarbital (Pentobarb, Abbott 
Laboratories, N Chicago, II). The intraperitoneal route was chosen to achieve a 
swift and effective anaesthesia of the donor animal which was euthanised on 
harvesting the heart. The chest was shaved and the animal intubated by direct 
vision with a 14G plastic cannula (Figure 2.1) and ventilated with 28% oxygen 
using a Harvard Rodent Ventilator (model 683, Harvard Apparatus, S Natick, 
Mass). The animal was placed supine and all four limbs were spread out and 
secured onto the operating platform with adhesive tapes. The chest and upper
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abdomen were cleansed with betadine solution and the area prepped with 
disposable drapes.
A median sternotomy was made and a retractor was used to spread the 
chest, exposing the pericardium. The pericardium was then incised and the 
heart exposed. The rat was then heparinised with 300 units of aqueous 
heparin injected into the inferior vena cava. Silk slings were placed around the 
innominate artery and the distal arch of the aorta (Figure 2.2). A 21 gauge IV 
cannula was inserted into the innominate artery and directed into the aortic 
root. The cannula was secured with the silk tie around the innominate artery. 
The cannula was then connected to the cardioplegic infusion line. Next, the 
venae cavae and pulmonary veins were ligated en block with a single 4-0 silk. 
The pulmonary artery was divided and the distal ascending aorta occluded 
using the silk sling placed earlier. The donor heart was arrested with an 
infusion of cold, dilute St Thomas’ cardioplegic solution delivered using a 
syringe pump at a rate of 0.44 ml/min. Following satisfactory cardioplegic 
arrest, the donor heart was excised and placed in a cold cardioplegic solution at 
4®C. A vhal solution was injected into the aortic root using the indwelling 
cannula with the distal aorta tied and the heart was then stored in cold 
cardioplegic solution until transplantation (Figure 2.3). During this time, the 
viral solution was in contact with the donor heart coronary system.
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Recipient: Anaesthesia and operation
Recipients, weighing 250-375 grams, were anaesthetised with haiothane 
and 02. The recipient animal was intubated using a 14 gauge IV cannula and 
ventilated with haiothane and oxygen.. This method of anaesthesia allowed for 
a more predictable time course in recovery from anaesthesia in the post­
operative period.
After propping and draping, a vertical midline abdominal incision was 
made to expose the abdominal aorta and inferior vena cava. The two vessels 
were separated over a segment below the renal vessels. The aorta was clamped 
proximal and distal to the site of anastomosis. The anterior wall of the aorta 
was lifted with a pair of forceps and a 2-3mm longitudinal incision was made. 
1 0 / 0  ethilon sutures were placed as stay sutures at each end of the incision in 
preparation for the anastomosis of the donor aorta. Heterotopic heart 
transplantation was performed by anastomosing the donor aorta to the side of 
the recipient's inffarenal aorta and the donor pulmonary artery to the 
recipient's inferior vena cava using continuous 10/0 ethilon suture (Figure 2.4). 
The inferior vena cava tie was first released followed by reperfusion from the 
aorta by the release of the aortic clamp (Figure 2.5). In most instances, the 
transplanted heart started beating spontaneously within 30 seconds. 
Haemostasis was then secured and the abdominal wound closed with 3-0 
vicryl suture. The haiothane was switched off and the animal extubated when 
breathing spontaneously. The animal was then recovered in a cage with 
supplementary oxygen via a face mask in a warm room. Intramuscular
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torbugesic was given as analgesia. In compliance with the biosafety guideline, 
the transplanted animals were housed in a dedicated room with biosafety level 
2 approval. Viability of the transplanted heart was checked by daily palpation 
of the beating heart.
Adenoviral vector delivery
A  volume of 350pl of viral solution (diluted in 2% fetal calf serum in 
199 medium) was used to transduce each donor heart in all experiments. Sham 
animals injected with the same volume of medium alone were used as controls. 
The volume for coronary injection in the rat heart was determined using 
medium stained with Evans Blue. The blue-stained medium was infused into 
the aortic root via a cannula as described above This technique was used in all 
the experiments in this study. Only one investigator performed all the 
operations in order to maintain consistency and to avoid major differences in 
infusion pressure. The volume of medium infused resulting in the effluent 
from the pulmonary artery becoming fully stained was determined in 5 animals 
and the mean volume (350 p.1) used in all further experiments. This was done
to ensure that the whole coronary system was exposed to the studied viral 
solution.
Specimen Preparation
The transplanted hearts were harvested at specified time-points in the 
protocol for histochemical analysis. The transplanted heart was removed and
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the coronary system flushed with PBS (Phosphate buffered saline). The 
midventricle was located by placing the explanted heart next to a mler. The 
heart was then cut with a razor blade to give a midventricular cross section of 
approximately 5 mm in thickness. This cross section was embedded in OCT 
compound (Elkhart, Ind) and snap frozen in an isopentane bath cooled in 
liquid nitrogen. Initially, the ventricular segments in OCT compound were 
snap frozen in liquid nitrogen directly. This resulted in an unacceptable degree 
of cytoarchitectural disruption of the histological sections. This was most 
likely due to the extreme temperature. However, the use of an isopentane bath 
in liquid nitrogen appeared to allow for a more controlled freezing of the 
specimens which resulted in better preservation of the cytoarchitecture.
Five 5pm thick cryostat sections were then cut at 25pm intervals. The 
25pm intervals was chosen to provide a reasonable degree of sampling of the 
mid-ventricular segment for transgene expression (Figure 2.6).
Histological Analys is
Staining for P-galactosidase Expression
In Specific Aims 1 and 2, the adenoviral vector coding for the reporter 
gene P-galactosidase, an enzyme present in Escherichia Coli, was used. The
ease and rapid in situ detection of p-galactosidase by 5-bromo-4-chloro-3-
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indoyl-p-D-galactopyranoside (X-Gal) staining allowed for an unambiguous 
and precise appreciation of adenoviral-mediated gene transfer. X-Gal is a 
substrate for p-galactosidase and the reaction releases the indoyl component 
giving the unmistakable blue staining of the transduced cells. Cells which had 
been transduced with a vector encoding the gene for P-galactosidase could be 
identified in vitro or in vivo by staining with X Gal. However, one caveat 
which should be borne in mind is the fact that normal tissue may stain blue if 
left exposed to the chromogenic substrate for a prolonged period of time. 
Thus, it is essential to limit the time of exposure to the chromogenic substrate 
in order to avoid spurious results. In all experiments described in this thesis 
staining for P-galactosidase was performed for four and a half hours.
Preparation of X  Gal solution:
X Gal solution is prepared as follows:
To make 10 mis of X-Gal solution mis, 
add 9 mis of distilled water
250pl of 2M Tris-HCl solution.
500pl of Ferriferrocyanide (2.5mM) solution (freshly made)
30pl of 5M NaCl solution
lOpl of IM MgC12 solution
125pi of X-gal (40 mg/ml) (Added last).
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Staining with X  Gal
5pm sections of hearts were fixed in 1.25% PBS/glutaraldehyde for 10
minutes at 4®C and rinsed three times with Phosphate buffered saline (PBS ).
The sections were then immersed in a solution of X-Gal for 4.5 hours at 37®C. 
The specimens were then rinsed in PBS and counterstained with eosin which 
gave a contrasting red stain. Blue stained cells indicated the presence of P- 
galactosidase expression.
H & Estaining
For assessment of rejection, Haemotoxylin and Eosin (H & E) staining 
was done for all transplanted hearts in the Specific Aim 3 study. The rejection 
scoring was done by an experienced cardiac transplantation pathologist who 
was blinded to the identification of the specimens. Rejection score was in 
accordance with the Heart Rejection Working Group
Mol ecu larand inunun o h istoch emi cal stain i ng
In Specific Aim 4, the detection of successful transduction of the 
transplanted heart with eNOS gene was done using molecular and 
immunohistochemical techniques. As these techniques were used only in the 
Specific Aim 4 study, full details will be given in the relevant Chapter in the 
thesis.
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Isolated Heart Perfusion: Langendoff Preparation
For functional studies in Specific Aim 4, the isolated heait perfusion 
model was used. The applicant was solely responsible for setting up this 
model and validating it (Figure 2.7). The guidelines were from the book "The 
Isolated Perfused Heart: According to LangendorfP' by H. J. Doring and H. 
Dehnert.
Studied animals were anaesthetised by intraperitoneal injection of 5 mg 
sodium per 100 gm body weight of pentobarbital (Pentobarb, Abbott 
Laboratories, N Chicago, II). The transplanted hearts were arrested with cold 
saline at 4 ® C, quickly excised and then mounted onto the aortic cannula of the 
Langendorff apparatus and perfused immediately with Krebs buffer 
(containing, in mmoFl: glucose 11.1, NaCl 118.3, KCl 4.7, MgSO^ 1.2, 
KH2 PO4  1.2, NaHCO] 25.0, CaCl2  2.5, Edetate Calcium Disodium 0.026, at 
pH 7.4 when gassed with 95% O2  plus 5% CO2 ). This expeditious manoeuvre 
was achieved by using a small vascular clip to secure the aortic root to the 
perfusing cannula. Once the heart was perfused and beating vigorously, the 
aorta was then secured with a silk tie and unwanted tissues were trimmed. 
Perfusion pressure was then set at 60mmHg. All hearts were paced using a 
Grass SD (Pacing Grass SD9 Stimulator, Quincy, MA) via the right atrium at 
320 beats/min. The environment around the heart was maintained with the use
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of a water-wai'med jacket. An in-line flow probe (Transonic System Inc, 
Ithaca, NY) was position above the aortic root to measure coronary flow. 
This equipment has been calibrated by the manufacturer and gave an accuracy 
to ± 0.5 ml/minute. The left atrium was then opened widely to facilitate the
introduction of an intraventricular balloon. The size of the intraventricular 
balloon (size 4, Radnotti, CA) was chosen to fit into the left ventricular 
chamber. This was cormected via a plastic cannula to a three way tap. One 
limb of the tap was connected to a Millar catheter (Millar Instrument Inc. 
Houston, Texas) for left ventricular measurement while the third limb was 
connected to a calibrated syringe filled with saline. This allowed the 
intraventricular balloon pressure to be varied. Following 15 minutes of 
stabilisation, left ventricular function curves were constructed by 
progressively increasing the volume of the balloon to achieve end-diastolic 
pressures. Following the assessment of cardiac function, the LVEDP was 
maintained at the optimal level and was heart allowed to stabilise again for 5 
minutes. Then coronary flow was measured at increasing time intervals (1 ,2 , 
3, 4, 5, 10, 15, 20, 25 minutes)
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Data Collection and Analysis
For quantitative analysis of gene transfer, the total number of positive 
staining cells per section were counted under magnification (x 1 0 0 ) and the 
mean value was calculated from five sections in each heart. All sections were 
reviewed by one investigator blinded to the identification of the sections. 
Furthermore, random slides were examined and counted by an independent 
person and results compared.
Results were expressed as median (and range) or mean (and standard 
deviation) of the number of positive staining cells per section in each group. 
The small sample size used in these experiments precluded the formal testing 
of the data for Gaussian distribution. Therefore, the characteristics of the data 
determined the statistical tests used. If the data suggested a non-Gaussian 
distribution and variances were unequal, despite log transformation, non- 
parametric tests were used. If the data suggested a Gaussian distribution and 
variances were equal, parametric tests were used. In all instances, a P value of 
< 0.05 was considered significant.
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Biosafety Issues: Precautions for working with
adenoviral vectors.
The use of biological vectors in gene transfer studies raises important 
biosafety issues. Adenovirus serotype 5 were used in all the experiments in 
this thesis.
There are more than 40 different human serotypes of adenoviins 
identified, of which types 2 and 5 have been extensively studied and used in 
gene transfer studies. The wild type adenovirus is known to cause mild 
respiratory infections which follows a self-limiting course in humans. None of 
the serotypes have been shown to have oncogenic potential. Although these 
vectors had been tested and shown to be replication defective, caution in 
handling these agents is necessary, in view of the complementary DNA 
(cDNA) inserts present in the recombinant adenovirus vectors. There is a 
theoretical risk of insertional mutagenesis in targeted organs. Also potential 
interaction with wild type adenovirus encountered in the environment may 
lead to a reversal of the replicative status of the vectors.
There are four different defined biosafety levels which consist of 
combinations of laboratory practices and techniques, safety equipment and 
laboratory facilities. Each combination is specifically appropriate for the 
operations performed, the route of transmission of the infectious agents, and 
for the laboratory function or activity. The recommended biosafety level(s)
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for organisms represent those conditions under which the agents can ordinarily 
be safely handled.
Working with adenoviral vectors represented a Biosafety level 2 risk 
(BSL-2). In brief. Biosafety level 2 practices, equipment and facilities 
applicable to clinical, diagnostic, teaching and other facilities in which work is 
done with the broad spectrum of indigenous moderate-risk agents present in 
the community and associated with human disease of varying severity. With 
good microbiological techniques, these agents can be used safely in activities 
conducted for the open bench, provided the potential for producing splashes 
or aerosols is low.
Therefore, in accordance with NIH (National Institute of Health) 
guidelines, all work with adenoviral vectors were performed in a BSL-2 
(Biosafety level 2) facility. However, due to the recombinant nature of these 
vectors, additional precautions as detailed below were adopted during these 
experiments.
Laboratory:
All adenovirus vector generation, propagation and purification were 
performed in a specified laboratory. This facility has a tissue culture area and 
has been certified as a BSL 2 facility by the Mayo Clinic Institutional 
Biosafety Committee. All tissue analysis was performed in laboratories that 
had limited access while experiments were in progress. Biohazard warning 
signs were posted and precautions for the disposal of sharp objects exercised.
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A biosafety cabinet was used for all manipulations involving recombinant 
adenoviral agents. Laboratory coats and gloves were worn at all times in the 
work area and removed prior to leaving. All laboratory waste were autoclaved 
prior to disposal.
Animal Facilities:
All animal procedures were performed in BSL 2 approved rooms. 
Heart transplantations were performed in the designated microsurgery room. 
All surgical drapes were disposable. After surgery, rats were housed in a 
designated room and access to the area was restricted when animals transduced 
with adenoviral vectors were present. Doors to the animal room opened 
inward, self-closing, and were kept closed when experimental animals were 
present. A hazard warning sign was posted, incoiporating the universal 
biohazard symbol, in which the presence of animals with adenoviral vectors 
were documented. All wastes from the animal room were autoclaved prior to 
disposal. Infected animal carcasses were incinerated after being transported 
from this room in leakproof, covered containers.
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Figure 2.1: Intubation for ventilation
A 14G plastic cannula was used to intubate the animal in preparation 
for ventilation.
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Figure 2.2: Aorta in preparation for cannulation
Silk slings were placed around the innominate artery and the aorta just 
distal to it. The innominate sling was used to secure the cardioplegia cannula 
and the aortic sling used as a cross clamp.
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Figure 2.3: Intracoronary viral infusion
Viral infusion into aortic root via indwelling cannula with the heart in 
cold cardioplegic solution.
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Figure 2.4: Heterotopic heart transplantation.
The ascending aorta of the donor heart is anastomosed to the abdominal 
aorta of the recipient using microsurgical techniques and instruments.
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Figure 2.5: Reperfusion of transplanted heart
On completion of the vascular anastomoses, the transplanted heart was 
reperfused by releasing the aortic tie.
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Mid-ventricular section Fixed, X-Gal stain, eosin Mean +ve cells per section
Figure 2.6: Assessment of gene transfer
Assessment of heart following gene transfer by light microscopy. Five 
slides of the mid-ventricular section were examined and the mean total of 
positive staining cells were counted and expressed as mean number of cells per 
section.
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From reservoir to replenish solution
W a r m e d  w a t e r  In - w a r m i n g  j a c k e t
Solution level se t  to g ive 60 mmHg perfusion pressure
Physiological Krebs solution
P r e s s u r e  M e a s u r e m e n t
Millar c a t h e t e r
In flow
S y r in g e
Intraventricular balloon
Heart
Figure 2.7: Schematic representation of the isolated heart perfusion model
This model of isolated heart perfusion was used to assess the functional 
effects of overexpression of eNOS in transplanted hearts.
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Chapter 3 : Adenoviral-Mediated Ex Vivo Gene 
Transfer To The Transplanted Heart: Effects Of 
Varying Vector Delivery Conditions.
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Introduction
Heart transplantation is an accepted treatment for end stage cardiac 
disease in selected patients However, limitations to clinical heart
transplantation include acute and chronic rejection, infection, and the side 
effects of immunosuppressive therapy. Gene therapy offers the potential for 
modifying these processes at the molecular level. In previous in vivo studies 
of vascular gene transfer, one challenge has been the need to interrupt blood 
flow to obtain luminal administration of recombinant DNA This limits 
the time in which the vector is in contact with target cells. Heart 
transplantation may be a more ideal setting for gene transfer as a more 
prolonged dwell time can be achieved during the necessary period of ischaemia.
Adenoviral vectors have been used to achieve efficient transfer and 
expression of recombinant genes in different vascular beds both ex vivo and in 
vivo One advantage of these vectors for gene transfer to the vasculatuie 
is the ability to transduce non-replicative cells. Adenoviral vectors can be 
grown to high titre and are not incorporated into the host cell genome 
rendering these vectors safer to work with. Earlier studies have demonstrated 
the feasibility of gene transfer to the transplanted heart with liposomal and 
adenoviral vectors However, the eonditions for optimal gene transfer to the 
transplanted heart using adenoviral vectors have not been defined. This series 
of experiments was designed to investigate the varying conditions for gene
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transfer in the heart transplant setting. Specifically, we sought to examine the 
effect of viral dose, the presenee of virus in the donor heart during warm 
ischaemia and the effect of increasing coronary distension by clamping the 
pulmonary artery during viral infusion.
Methods
Animals
Inbred male Lewis rats weighing 250 to 320 grams were used as 
syngeneic donors and recipients. All post-operative rats received analgesia and 
were allowed to recover with supplementary oxygen in a warm environment.
Adenovirus Vector
A first generation Ela-deleted (replication-defective) and non-nuclear- 
targeted adenovirus vector encoding for p-galactosidase (AdLacZ) under the
control of the CMV promoter was used in these experiments. The 
recombinant virus was propagated, isolated and purified as described in 
Chapter 2. Viral titres were determined by plaque assay and expressed as 
plaque forming unit per ml (pfu/ml).
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Operation and Gene Transfer
Abdominal heterotopic heart transplantation using standard 
microsurgical techniques was performed The technical details have been 
described in Chapter 2. A volume of 350|xl of viral solution (diluted in 2% 
fetal ealf serum in 199 medium) was infused over 5 seconds into the coronary 
arteries via the aortic root. After 60 minutes of cold storage at 4°C, all donor 
hearts were heterotopically transplanted into the recipients. Function of the 
grafts was assessed daily by palpation of the beating transplanted heart.
Experimental Groups
In experiment A, the pulmonary artery was left open during viral 
infusion and at the end of 60 minutes the virus was flushed out with repeat 
infusion of cold cardioplegic solution prior to transplantation. A dose 
response experiment was carried out to determine the optimal viral
concentration for gene transfer under these conditions. Viral concentrations of
7 8 91x10  pfu/ml (n=5), 1x 1 0  pfu/ ml (n=5), 1x 1 0  pfu/ ml (n=6 ), and medium 
only as control (n-5) were used. The most effective viral concentration was 
then used in subsequent experiments (below) to compare the efficiency of gene 
transfer under different conditions.
In experiment B, using the viral concentration as determined in the
9
initial experiment (1 x 1 0  pfu/ml), the pulmonary artery was clamped during
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viral infusion and the virus was not flushed out with cold cardioplegic solution 
at the end of 60 minutes prior to performing heart transplantation ( n = 6  ).
Having determined the above improved conditions for gene transfer, a
further dose response study (experiment C) was carried out with two
8 10 
additional viral concentrations (1 x 10 pfu/ml and 1 x 1 0  pfu/ml, n = 4 for
each group) to determine the optimal concentration for gene transfer under the
conditions of experiment B.
To further investigate the conditions that resulted in efficient gene
transfer in experiment B, further experiments were performed. In
experiment D, the role of increased coronary distension during viral infusion
9
alone on the efficiency of gene transfer was studied. A viral solution of 1 x 10 
pfu/ml (as determined in previous experiments) was infused into the aortic 
root with the pulmonary artery clamped, resulting in the coronary system 
visibly distended, and the virus was then flushed out with cold cardioplegic 
solution at the end of 60 minutes prior to performing heart transplantation ( n 
= 6  ). This was compared with experiment E, in which the role of virus 
warm dwell during transplantation on gene transfer efficiency was evaluated.
9
A viral solution of 1 x 10 pfu/ml (as determined in previous experiments) was 
infused into the aortic root with the pulmonary artery open, and the virus was 
not flushed out with cold cardioplegic solution at the end of 60 minutes prior 
to performing heart transplantation ( n = 5 ).
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In addition, the aortic root pressure was measured, using a pressure 
transducer, during viral infusion with and without the pulmonary artery 
clamped.
Heart Retrieval andHistochemical Analysis
Four days after surgery, transplanted hearts were harvested and 
processed as previously described. Briefly, the explanted heart was cut into 
three sections, apical, midventricular and basal, with a razor blade. The 
location of the midventricular section was estimated using a ruler. The section 
was then snap frozen. Five 5pm thick cryostat sections were cut at 25 pm 
intervals in the mid-ventricular section. The specimens were fixed and stained 
in a solution of X-Gal, then counterstained with eosin. Blue stained cells 
indicated the presence of P-galactosidase expression. For quantitative
analysis, the total number of positive staining cells per section were counted 
under magnification (x 1 0 0 ) and the mean value was calculated from five 
sections in each animal.
Statistical Analysis
Results were expressed as median (range and standard error) of the 
number of positive staining cells per section in each group. As the data did not 
follow a Gaussian distribution and variances were unequal, a non-parametric 
test (Kruskal-Wallis) of analysis of variance was performed to evaluate overall
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group differences for more than two groups. If overall significance was 
present, Dunn’s post hoc test was used for pairwise comparisons. For 
comparison between two groups, the Mann-Whitney test was used (Prism, 
GraphPad, San Diego, CA). A P value of < 0.05 was considered significant.
Results
Operative mortality was 6 %. All transplanted hearts were beating at 
the time of harvest. The mean transplant time (during implantation of the 
donor heart) was 29.7 minutes (range from 25 minutes to 35 minutes). There 
were no differences in ischaemic times between the groups.
In the initial dose response study (experiment A), the median (range 
and standard error of mean, SEM) of the total number of positive staining cells
7
for P-galactosidase per section was 0.2 (0 - 1.8, SEM 0.34) in the 1 x 10
8
pfu/ml group, 1.8 (0 - 12.6, SEM 2.44) in the 1 x 10 pfu/ml group and 17.8
9 7
(0.6 - 37.6, SEM 5.03) in the 1 x 10 pfu/ml group (p < 0.05, 1 x 1 0  pfu/ml vs
9
1 X 10 pfu/ml) (Figure 3.1). All sham transplanted heart stained negative for 
p-galactosidase.
In experiment B, a combination of clamping the pulmonary artery 
during viral infusion with a period of viral warm dwell, by not flushing the 
coronary system, was evaluated. Coronary distension was visibly greater than
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when the pulmonary artery was clamped during the viral infusion. The median 
(range, SEM) of the total number of positive staining cells for p-galactosidase
9
was 238.1 (32 - 608.2, SEM 91.48) in the 1 x 10 pfu/ml group. This resulted
9
in a significant increase in gene transfer (p < 0.005) compared with the 1 x 10 
pfu/ml group in experiment A (Figure 3.2).
Having determined that experiment B represented dramatically 
improved conditions for gene transfer, a further dose response evaluation
(experiment C) was carried out with two additional viral concentrations (1 x
8 10 
10 pfu/ml and 1 x 1 0  pfu/ml) under the same conditions as experiment B.
The median (range, SEM) of the total number of positive staining cells for p-
8
galaetosidase was 0.4 (0 - 0.8, SEM 0.18) in the 1 x 10 pfu/ml group and 276
10
(109 - 564.2, SEM 108.7) in the 1 x 10 pfu/ml group. There was no
9 10
difference in efficiency of gene transfer between 1 x 1 0  pfu/ml and 1 x 1 0  
pfu/ml, but gene transfer was significantly less efficient when a concentration
of 1 X 10^ pfu/ml was used (p<0.05) (Figure 3.3).
9
In experiment D, viral solution of 1 x 10 pfu/ml was infused into the 
aortic root with the pulmonary artery clamped, resulting in the eoronary 
system visibly distended and the virus was then flushed out with cold 
cardioplegic solution at the end of 60 minutes prior to transplantation. The 
median (range, SEM) of the total number of positive staining cells for p- 
galactosidase was 90.2 (25.8 - 118, SEM 13.94). In experiment E, to evaluate
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the effect of warm dwell, viral solution of 1 x 1 0  pfu/ml was infused into the 
aortic root with the pulmonary artery opened, and the virus was not flushed 
out with cold cardioplegic solution at the end of 60 minutes prior to 
performing heart transplantation. The median (range) of the total number of 
positive staining cells for p-galactosidase was 3.8 (1.2 - 93.4, SEM 17.8). The 
efficiency of gene transfer in group D was significantly greater than group E (p 
< 0.05) (Figure 3.4).
There was no significant difference in the aortic root pressure during 
viral infusion whether the pulmonary artery was clamped or not. The mean 
pressure reached was 79 mm Hg. The aortic root pressure dropped rapidly to 
preinfusion level at the end of viral infusion. However, the coronary system 
remained visibly more distended during and after the viral infusion in hearts in 
which the pulmonary artery was clamped.
The cell types which stained positively for P-galactosidase included 
cardiomyocytes, endothelial cells and fibroblasts (Figures 3.5). The smooth 
muscle cells in the coronary arteries did not stain positive for p-galactosidase.
Transduction of cardiomyocytes appeared to be the most efficient of all the 
cell types. There was no consistent pattern of distribution of staining with the 
exception that staining appeared somewhat more accentuated around 
subepicardial zones of organising ischaemia. There was no difference in the 
extent of transgene expression through both right and left ventricles. All sham 
sections stained negatively including areas of ischaemic damage. There were no
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inflammatory cells seen in either sham or p-galactosidase transduced 
transplanted hearts.
Discussion
This series of experiments was designed to determine the conditions for 
optimizing gene transfer in the heart transplant setting. We sought to perform 
experiments with conditions relevant to clinical transplantation. In agreement 
with an earlier study using a mouse model the results showed that gene 
transfer to the transplanted heart using adenoviral vectors is feasible. The 
efficiency of gene transfer, however, was markedly affected by the 
experimental conditions.
In clinical heart transplantation, there is up to approximately four 
hours delay from the time of organ retrieval to transplantation when the donor 
heart can be safely preserved Although this may allow for a prolonged viral 
dwell time for gene transfer, the conditions of organ preservation may have a 
marked effect on the efficiency of gene transfer. A previous study showed 
that adenovirus vectors could efficiently transduce hepatocytes in vitro at 4^C 
but the efficacy was affected by the preservation solution used
In the present experiments, the whole organ was the target for gene 
transfer. In the initial dose response experiments, gene transfer at 4^C,
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although dependent on vector dose, was inefficient. This level of gene transfer 
may well be inadequate for effective clinical gene therapy. The reason for the 
inefficieney was unclear. Adenoviral uptake into cells occurs via receptor- 
mediated endocytosis and the rate of incorporation into the target cells is 
temperature dependent Recently, the steps involved in the attachment and 
internalisation of the adenovirus in cells were defined The expressions of 
the CAR (coxsackie and adenovirus receptor) and ttvPs integrin in the target
cells are important for efficient adenovirus-mediated gene transfer In
addition, it is also known that anatomical barriers may impose significant 
limitations on the penetration of adenoviral vectors The penetration of 
particles in the size range of adenoviral vectors in the arterial system is 
dependent on the distending pressure We therefore evaluated the potential 
benefits of further distending the coronary system and leaving virus in the 
donor heart during warm ischaemia by clamping the pulmonary artery during 
viral infusion and not flushing out the viral solution prior to transplantation in 
experiment B. This resulted in a highly significant improvement in the 
effieiency of gene transfer. It was noted that four transduced hearts did not 
show any positive cells for P-galactosidase (experiment A, 2  at 1 x 10  ^pfu/ml, 
1 at 1 X lO^pfu/ml and experiment B, 1 at 1 x lO^pfu/ml). All hearts 
transduced at higher concentrations of virus showed positive transgene 
expression with X-Gal staining. Therefore, the reason for failing to achieve 
gene transfer in a few of the animals was likely to be related to inadequate 
viral concentrations for the method of gene delivery used. Biological
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variability may also have contributed. However, successful gene transfer was 
consistently achieved with viral concentrations of 1 x lO^pfu/ml or greater. 
Therefore, all subsequent studies in this thesis were performed with this 
concentration of virus.
To further evaluate the effect o f further distension of the eoronary 
system during viral infusion and virus dwell in warm ischaemia, experiments D 
and E were performed. The results in experiments D and E suggested that 
coronary distension during viral infusion alone played a greater role in the 
improved efficiency of gene transfer than a period of virus dwell during warm 
ischaemia. Although the aortic root pressures measured did not differ during 
viral infusion with the pulmonary artery open or clamped, this did not exclude 
the possibility of greater distension in the microvascular system in the latter. 
Hajjai' et showed successful gene transfer to the heart by infusing viral 
solution into the coronary system with the distal aorta and pulmonary artery 
clamped as in experiment B. However, he did this in an in vivo rat model with 
the heart beating. He introduced a cannula into the aortic root via the apex of 
the left ventricule and subsequently injected the adenoviral vector with the 
distal aorta and pulmonary artery clamped. The viral solution was allowed to 
dwell for 10 seconds. This method effectively increased the perfusion pressure 
down the coronary system during viral infusion and also had the benefit of 
pulsatile flow. Both these factors may contribute to improved gene transfer 
efficiency. However, in the setting of clinical transplantation, myocardial 
preservation is paramount. With this in vivo method of gene transfer, the left
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ventricular apical puncture and the distension of the ventricles during 
isovolumetric contractions may significantly add to the myocardial insult 
already sustained by the donor heart during prolonged cold ischaemic 
preservation. Donahue et aP  ^ demonstrated that efficiency of adenoviral- 
mediated gene transfer to the heart by intracoronary infusion of the viral vector 
was dependent on the delivery flow rate. The authors hypothesised that flow 
above a critical rate opened precapillary sphincters and allowed enhanced 
perfusion of myocardial capillaries, thus maximising the surface area of virus 
delivery and reducing diffusion distances.
Having identified that the conditions in experiment B resulted in 
efficient gene transfer, the second dose response experiment showed that a
9
viral concentration of 1 x 10 pfu/ml remained the most effective dose. The 
reason for this is unclear but it appears that there is a threshold concentration 
before efficient gene transfer occurs. In addition, increasing the viral 
concentration by 1 0  fold to 1 x 1 0 ^^  pfu/ml did not increase the efficiency 
significantly. Higher concentrations of viruses were not used due to the large 
amount of virus required and also to avoid the potential for cytotoxicity.
To further illustrate the importance of optimising conditions for gene 
transfer, Donahue et af^ recently attempted to accelerate and improve the 
efficiency of gene transfer to ex vivo rabbit hearts by manipulating the solution 
for adenoviral coronary infusion. He exploited the fact that agents like 
serotonin and bradykinin were known to increase vascular permeability. The 
integrity of endothelial tight junctions which are regulated by cadherins and
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dependent on calcium concentration was also exploited by maintaining a low 
concentration of calcium in the viral solution. A combination of serotonin and 
low calcium solution resulted in highly effective and rapid gene transfer.
Several methods of gene transfer to the heart have been studied 
including direct myocardial injection and intracoronary infusion The 
effectiveness of direct injection was limited by the spatial expression and also 
the consistent intense inflammatory response seen in the needle track The 
present study demonstrated that intracoronary viral infusion resulted in 
widespread distribution of gene expression and the efficiency of gene transfer 
was enhanced by coronary distension and a period of warm ischaemia. No 
inflammatory cells were seen in either sham or p-galactosidase transduced
transplanted hearts. This was similarly reported in other s t u d i e s ^ A l l  
histological sections were examined by an experienced pathologist. However, 
as the hearts were only examined 4 days after transduction, the presence of 
inflammatoiy responses could not be excluded if the hearts were examined at 
other time-points. Therefore, under the conditions of the experiments, there 
was no evidence of adenoviral-mediated cytotoxicity.
There were areas of ischaemic damage predominantly in the epicardial 
region. This was most likely due to the inevitable rewarming of the heart 
during the transplant procedure and the epicardium was most vulnerable due to 
the intense heat from the operating lights. Although the accentuation of 
positive staining in zones of organising ischaemia suggested the relevance of 
warm ischaemia to gene transfer efficiency this was not supported by the
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findings in experiment E. The reason for this remained unclear. Recently, 
Wright et al^  ^ showed artefactual P-galactosidase staining in necrotic
myocardium of rabbit hearts transduced using cationic liposomes or infarcted 
using coil embolization. Consistently, inflammatory cells were seen in these 
areas of necrotic myocardium. These cells are known to have high level of 
endogenous P-galactosidase^^ and the authors suggested this as a possible
explanation. However the species, vector, mechanism of infarction and 
method of staining were different from the present experiments. The level of 
endogenous p-galactosidase is species-dependent^^and this may be another 
faetor. In the present experiments, all sham sections (as control) stained 
negatively for P-galactosidase including areas of ischaemic damage suggesting 
that artefactual staining was not a problem. However, a cautionary approach 
to interpreting p-galactosidase staining results should be adopted in view of
these potential pitfalls.
Although it appeared as though the effieiency of gene transfer was 
greater in cardiomyocytes compared to endothelial cells, there were many more 
cardiomyocytes per cross section of myocardium. We did not determine 
efficiency of gene transfer by cell type, but similar observations have been 
made in other animal models If it is true that gene transfer is greatest in 
cardiomyocytes, the reason is unclear, but may be related to differential 
expression of CAR receptors in the different cell types. There was also 
considerable inter-animal variability in the expression of the transgene. This
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may be due to the technique of gene delivery or a reflection of the biological 
variability of gene transfer. Other studies^^’^  ^ have also reported considerable 
variability in transgene expression. This variability may compromise clinical 
gene therapy.
Finally from a biosafety standpoint, although conditions in experiment 
B were effective in gene transfer, the prolongation of viral dwell time into the 
period of warm ischaemia and not subsequently flushed out raises concerns 
related to the subsequent distribution of the virus to other tissues when blood 
circulation is restored. This will need to be investigated further.
In summary, we have demonstrated a method of adenoviral 
administration and defined conditions for effective gene transfer to the 
transplanted rat heart. This method of delivery was used in all subsequent 
experiments.
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Figure 3.1: Experiment A; A dose response study
Effect of viral dose on the efficiency of gene transfer in the 
transplanted heart in a syngeneic rat abdominal heart transplantation model 
under conditions of experiment A, as defined in the text. Data represents 
median (range) of the number o f positively stained cells for p-galactosidase per 
section. Asterisk (*) denotes significant difference compared to 1 x lO’ pfu/ml 
dose (Kruskal-Wallis, Dunn post hoc, p < 0.05), n = 5 for groups 1 x 10  ^
pfu/ml and 1 x 1 0 ® pfu/ml, n= 6  for group 1 x 1 0  ^pfu/ml.
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Figure 3.2: Experiment A vs B
Effect of different experimental conditions (experiment A and B), as 
defined in text, on the efficiency of gene transfer in the transplanted heart. 
Viral dose o f 1x10^ pfu/ml was used and n = 6  in each group. denotes 
median value. Asterisk (*) denotes significant difference compared to 
experiment A (Mann-Whitney test, p < 0.05).
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Figure 3.3: Experiment C
Effect of viral dose on the efficiency o f gene transfer in the 
transplanted heart in a syngeneic rat abdominal heart transplantation model 
under conditions of experiment C, as defined in the text. Data represents 
median (range) o f the number of positively stained cells for p-galactosidase per
section. denotes median value. Asterisk (*) denotes significant
difference compared to 1 x 10® pfu/ml dose (Kruskal-Wallis, Dunn post hoc, p 
< 0.05), n -  4 for groups 1 x 10® pfu/ml and 1 x 10^ ® pfu/ml, n= 6  for group 1 x 
1 0  ^pfu/ml.
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Figure 3.4: Experim ent D vs E
Efficiency of gene transfer under conditions in experiment D compared 
to E as defined in the text. The conditions in experiment D resulted in 
significantly greater level o f transgene expression than experiment E (Mann- 
Whitney test, p< 0.05)
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Figure 3.5: X Gal staining of control heart
Myocardium from control animal (experiment A), showing no blue 
staining, indicating a lack of adenoviral mediated gene transfer of the p- 
galactosidase gene, x 200
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Figure 3.6: Distribution of transgene expression
Myocardium from animal in experiment B showing overall staining 
intensity and distribution of expression of the p-galactosidase gene as indicated 
by the blue stained cells. Note positive cells in area of organising ischaemia 
(arrow) x 100
94
fFigure 3.7: Gene transfer to cardiomyocytes and endothelial cells
Myocardium from animal in experiment B showing transduction of 
cardiomyocytes and endothelial cells, x 400.
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Chapter 4 : Influence of Temperature on In 
Vitro Adenoviral-mediated Gene Transfer
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Introduction
A significant obstacle to gene therapy is the difficulty of transferring 
genes to cells and tissues in vivo. In contrast to in vivo vascular gene transfer, 
transplantation may represent an ideal setting for administration of the vector 
via the blood vessels as the inevitable period of donor organ ischaemia 
following harvesting allows a prolonged dwell time within the target tissue. In 
the previous chapter, the efficiency of gene transfer was markedly affected by 
conditions of vector delivery. The efficiency of gene transfer during the period 
of cold ischaemia may be influenced by the low temperature of the 
preservation solutions. The endothelial surface represents the initial barrier to 
gene transfer in the heart. This study was designed to examine the effect of 
temperature on the efficiency of adenovirus-mediated gene transfer to 
endothelial cells in vitro. As this is an in vitro cell culture study, the 
conditions for gene transfer would be different from that to an intact organ. 
Therefore extrapolating the results to an ex vivo or in vivo gene transfer to an 
intact organ setting should be done with caution.
Methods
Adenovirus Vector
A replication defective, Ela-deleted serotype 5 adenoviral vector
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encoding for P-galactosidase, under the control of the CMV promoter was
used in this study. The propagation and purification of the vector have been 
previously described in Chapter 2.
Transduction of cells in vitro
Endothelial cells were purchased from Clonetics Corporation (San 
Diego, CA). They were grown in endothelial cell basal medium without 
phenol red (Clonetics Corporation, San Diego, CA) supplemented with human 
recombinant epidermal growth factor (0 . 0 1  ng/ml), hydrocortisone ( 1  p,g/ml),
gentamicin (50 jxg/ml), amphotericin B (0.05 iLig/ml), bovine brain extract (12
p.g/ml ) and 2  % fetal bovine serum.
Endothelial cells were incubated in a humidified, 5% carbon dioxide 
atmosphere at 37° C and routinely passaged just before reaching confluence by 
brief exposure to trypsin-EDTA solution (trypsin 0.05%, EDTA 0.53 mM; 
Gibco BRL, Gaithersburg, MD). Cells at passage 4 - 8  were used in all 
experiments. 5x10* cells were plated on 6 -well plates and allowed to attach 
overnight.
After removal of medium, cells were washed twice with phosphate- 
buffered saline (Gibco BRL, Gaithersburg, MD) and then incubated for 1 hour 
in 0.5 ml of phosphate-buffered saline + 0.1 % bovine serum albumin 
containing 2 x 1 0  ^ pfu/ml, which was equivalent to a multiplicity of infection 
(MOI) of 200. MOI is equivalent to the number of viral particles per cell.
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Endothelial cells were incubated at three different temperatures: 4°C, 10°C and
37°C. At the end of incubation period the cells were washed twice with
phosphate-buffered saline and incubated for 24 hours in fresh medium. In all 
experiments (n = 4), 12 wells for each cell type at each incubation temperature 
were used. Control cells were incubated using the same experimental 
conditions in virus-free phosphate-buffered saline + 0 . 1  % bovine serum 
albumin.
Twenty four hours later cell viability was assessed by trypan blue 
exclusion. The viability of two wells was evaluated using a standard 
haemocytometer following detachment of cells by trypsin-EDTA solution.
Prior to staining for |3-galactosidase, endothelial cells were washed 
twice with phosphate-buffered saline and fixed for 15 minutes in 1.25% 
glutaraldehyde at 4° C. After a further rinse in phosphate-buffered saline, the 
cells were stained in a solution of 500 |ig/ml X-Gal for 4.5 hours at 37° C. 
Blue stained cells indicated the presence of P-galactosidase expression. For 
quantitative analysis, the total number of positively staining and negative cells 
were counted manually by an observer blinded to experimental groups using an 
inverted bright light microscope (magnification = 200x). Fourteen randomly 
selected fields in each well were evaluated. The percentage of transduced cells 
was calculated as the number of positively staining cells divided by the total 
number of counted cells x 1 0 0 .
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Statistical analysis
Results were expressed as mean ± standard deviation. The
characteristic of the data suggested equal variances. The analysis of variance 
(parametric) was performed to evaluate overall differences between the three 
groups. If overall significance was present, Bonferroni's post hoc test was 
used for pair comparisons (Prism, GraphPad, San Diego). A P value of less 
than 0.05 was considered significant.
Results
In vitro Gene Transfer to Cells
Toxicity, the viability assessed at the end of the 24 hours incubation ranged 
from 75 to 80 % in endothelial cells transduced at 4° C and 10° C and from 80 
to 85 % in cells transduced at 37° C.
Human umbilical vein endothelial cells: following transduction at 4° C and 
10° C, the percentage of cells positively stained for p-galactosidase was 14.29 
± 3.79 % and 12.43 ± 2.47 %, respectively. No significant difference was 
noted between these groups. In contrast, when the cells were transduced at 
37° C, the positively stained cells were 30.55 ± 7.26 % (p < 0.01 vs. 4° C and
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10° C) (Figure 4.1). Control endothelial cells, not exposed to the adenoviral 
vector, stained negative for p-galactosidase.
Discussion
As donor organs are preserved at 4° C, the effect of temperature on
gene transfer is an important question. The present study demonstrates that 
efficiency of adenoviral-mediated gene transfer to endothelial cells in vitro is 
significantly influenced by temperature. This may represent an impediment to 
adenoviral-mediated gene therapy in the setting of clinical transplantation as 
during retrieval, the donor organ is perfused and stored in cold preservation 
solution to preserve cellular viability until the transplant procedure can be 
accomplished. Although transplantation may be an ideal setting for gene 
therapy, as a prolonged dwell of the vector in the target organ can be achieved 
during this inevitable period of ischaemia, gene transfer may be influenced by 
the low temperature of cold preservation.. In the previous chapter, it was 
noted that transgene expression was accentuated in superficial and less well 
preserved areas of the heart. This observation suggested the role of 
temperature on the efficiency of gene transfer as the subepicardial layer of the 
heart rewarmed quicker, during the transplant procedure, due to its proximity 
to the operating light source.
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The effect of temperature on the gene transfer has not been fully 
addressed. In a study by Csete et al, gene transfer to the donor liver was not 
affected by low temperature^*. After 1 hour exposure to the adenoviral vector 
at 4° C, efficient transduction was noted (about 80 % of hepatocytes showed
positive staining for the reporter gene). However, this high efficiency may be 
related to the marked tropism of this vector for hepatocytes. In another 
report, adenoviral-mediated gene transfer to endothelial cells in vitro, in organ 
cultures and in vivo was influenced by temperature^^. In that study, efficiency 
of gene transfer to vascular endothelial cells in vitro appeared to be dependent 
on the titre of the viral solution, whereas the endothelium in situ seemed to be 
resistant to adenoviral infection even at the highest viral titre ( 1 0 ^^  pfu/ml). 
The latter finding has not been observed by others. In contrast, Chapelier et 
al. have demonstrated that efficiency of adenoviral gene transfer to 
endothelial cells was significantly impaired at 10° C. The results from the 
present study are consistent with those of Chapelier. Recently, Donahue et 
al^^  proposed altering the conditions for adenoviral gene transfer by using a 
viral solution which was low in calcium and had serotonin added. The effect 
of both these components theoretically increases the permeability of the 
endothelial barrier to gene transfer. Further techniques of optimising 
conditions for gene transfer were discussed in the previous chapter.
In clinical transplantation, efficient gene transfer to the donor organ will 
be necessary at 4° C. If inefficient, gene transfer in this setting results in
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generation of low quantities of biologically active transgene, efforts will be 
needed to improve gene transfer efficiency at this temperature. Although 
increasing the dose o f the vector may enhance gene transfer efficiency, this 
may also augment the risk of vector-induced toxicity. As efficiency of 
adenoviral gene transfer is directly related to the length of exposure to the 
vector^^, improvement of donor organ preservation may allow more prolonged 
dwell time within the target organ and thus may afford enhanced gene transfer 
efficiency.
Finally, there are clear differences between the environmental 
conditions of in vitro cell culture and intact organ. The mam advantage of 
using an in vitro cell culture technique for testing the role of temperature in 
adenoviral gene transfer is the ability to control the environment precisely. In 
addition, the cells of in vitro culture may be exposed directly to the adenoviral 
vector and gene transfer may be achieved at a lower and defined concentration. 
One of the disadvantage of cell culture environment includes the loss of 
specific cell interactions which are characteristics of intact organs. This may 
significantly alter the efficiency of gene transfer in an intact organ. In addition, 
it also lacks the systemic components that may influence the efficiency of gene 
transfer in an intact organ in vivo. Therefore , as long as the limitations of the 
in vitro cell culture technique are appreciated, it can be a valuable tool for 
studying gene transfer.
In summary, this study demonstrates that efficiency of adenovirus- 
mediated gene transfer to endothelial cells is significantly reduced by low
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temperature. Requirement o f donor organ cold preservation may undermine 
the effectiveness of gene therapy in the transplant setting.
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Figure 4.1: Effect of temperature on in vitro gene transfer
Effect o f incubation temperature on gene transfer efficiency to 
human umbilical vein endothelial cells (HUVEC). Multiplicity o f  
infection = 200. Data represent mean ± SD o f the percentage o f cells 
positively staining for the reporter gene (wells no. = 10, ejq)eriment 
performed on 4 separate occasions). Asterisks denote significant 
difference compared to cells at 4° C and 10° C (ANOVA, Bonferroni’s 
post hoc test, p < 0.05)
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Chapter 5 : Immunosuppression Prolongs 
Adenoviral-Mediated Transgene Expression in 
Cardiac Allograft Transplantation.
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Introduction
Chapter 1 demonstrated the feasibility and efficiency of adenoviral- 
mediated gene transfer in the heterotopic heart transplantation model. 
However, one major limitation of first generation adenoviral vectors has been 
the transient nature of transgene expression. In previous studies using 
adenoviral vectors, transgene expression was lost or greatly diminished after 30 
days Although the reason for this is not entirely clear, cell mediated
immune responses appear to play an important role in the initial loss of 
transgene expression and the development of neutralising antibodies by 
activated B cells reduces the effectiveness of subsequent adenoviral 
transduction The prolongation of transgene expression in transduced
immunologically immature neonatal animal models ^^and with the use of 
immunosuppression ^*further supports the role of the immune system in this 
process.
In the heart transplantation setting, the necessary use of 
immunosuppression and the possibility of a prolonged viral dwell time during 
the period of donor organ ischaemia may be a more ideal setting for efficient 
gene tiansfer and prolonged transgene expression. In addition, readministration 
of the adenoviral vector may not be applicable in this setting as direct access to 
the heart may be impractical. This study therefore hypothesises that in the
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setting of heart transplantation, the routine use of immunosuppression will 
prolong transgene expression in adenoviral-mediated gene transfer.
Methods
Adenovirus Vector
A replication defective adenovirus vector encoding for p-galactosidase 
under the control o f the CMV promoter was used as reporter gene. The 
recombinant virus was propagated in 293 cells and then isolated and purified 
as described in Chapter 2.
Animals
A total of 152 rats (donors and recipients) were used in these 
experiments. Inbred male Lewis (RT-1^) rats were used as syngeneic donors 
and Brown Norway (RT-1^) rats were used as allogeneic donors. All 
recipients were Lewis rats (RT-1^).
Operation and Gene Transfer
Rat heterotopic abdominal heart transplantations, using standard 
microsurgical techniques as described in Chapter 2, were performed.
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The donor hearts were transduced with adenoviral vectors under 
conditions defined in Chapter 2 that resulted in the most efficient gene transfer 
(in experiment B). Briefly, a volume of 350|il of viral solution at a
9concentration of 1 x 10 pfu/ml was infused over 5 seconds into the coronary 
arteries via the aortic root. The pulmonary artery was clamped dui'ing viral 
infusion and the virus was not flushed out at the end of 60 minutes cold 
storage prior to performing heart transplantation. All donor hearts were 
heterotopically transplanted into the abdomen of the recipients. The total 
period of incubation with the virus was 90 minutes with 60 minutes cold 
ischaemia during the cold storage period plus a further 30 minutes of warm 
ischaemia during the transplant procedure when inevitable rewarming of the 
heart occurs. Function of the grafts was checked daily by palpation of the 
beating transplanted heart.
Experimental Groups
The duration of transgene expression was examined following:
a) syngeneic transplantation in non-immunosuppressed animals (Group A),
b) syngeneic transplantation in immunosuppressed animals (Group B)
c) allogeneic transplantation in immunosuppressed animals (Group C).
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Immunosuppressed animals were given cyclosporine by daily 
orogastric injections from the day of surgery. The cyclosporine dose was 
lOmg/kg/day for the first 2 weeks after transplant and 5mg/kg/day thereafter 
until harvest This dosage was chosen as a balance between effective 
immunosuppression and fatal toxicity of the drug. All animals were weighed 
weekly for dose adjustment. After transplantation, animals were studied at 1, 
4, 8  and 12 weeks (n= 6  in each group for each time point giving a total number 
of 72 transplants). These prolonged time points were chosen to study the 
effect of immunosuppression on the duration of transgene expression. 
Previous studies^ '^^^^ had shown that 30 days after adenoviral-mediated gene 
transfer, transgene expression was lost or greatly diminished. However, the 
study suggested that immunosuppression may prolong transgene expression 
but the duration was not investigated.
Heart Excision, Histochemical Analysis and Rejection Staging
At the termination of the experiment, transplanted hearts were 
removed and flushed with saline. Specimens for analysis were prepared as 
described in the methods section of Chapter 2. Blue stained cells indicated the 
presence of p-galactosidase expression. The overall mean values of 5 
midventricular sections were calculated for each group and the results 
expressed as mean and median number of positively stained cells per section 
were then analysed. For assessment of rejection, formalin preserved heait
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sections were embedded in paraffin, cut, stained with haemotoxylin and eosin 
and then scored according to the guidelines set by the Heart Rejection Working 
Group All slides were read by an experienced cardiac pathologist blinded to 
the identification of the slides.
Statistical analysis
Results were expressed as mean ± standard deviation, and median
(range) of the number of positive staining cells per cross section. As the data 
did not follow a Gaussian distribution and variances were unequal, a non- 
parametric test (Kruskal-Wallis) of analysis of variance was performed to 
evaluate overall group differences for more than two groups. If overall 
significance was present, Dunn’s post hoc test was used for pair comparisons 
(Prism, GraphPad, San Diego, CA). A p value of < 0.05 was considered 
significant.
Results
Two animals died early, from post-operative bleeding, and at 8  and 12 
weeks giving an overall mortality of 5%. All transplanted hearts in the study 
were beating at the time of harvest.
I l l
Group A (Non-immunosuppressed syngeneic): The total number of 
positively stained cells for p-galactosidase activity was 240.6 ± 171.9 (mean ±
standard deviation) with a median range of 254.3 (24-510.6) at 1 week, 0.1 ± 
0.1 and 0.1 (0-0.2) at 4 weeks, 0.03 ± 0.08 and 0 (0-0.2) at 8  weeks and 0.7 ± 
0.8 and 0.4 (0-2) at 12 weeks. (Kruskal-Wallis, non parametric ANOVA, 
p<0.05 for all time-points comparisons) (Figure 5.1). Four weeks after 
transduction, transgene expression was virtually undetectable.
Group B (Immunosuppressed syngeneic): The total number of
positively stained cells was 374.2 ± 488.2 and 218 (7.4-1307) at 1 week, 142.5
± 135.2 and 80.5 (18.6-321.8) at 4 weeks, 44.2 ± 48.1 and 31.2 (0.4-121.4) at
8  weeks and 13.7 ± 23.7 and 4.8(0-61.6) at 12 weeks (Kruskal-Wallis, non
parametric ANOVA, p<0.05 for all time-points comparisons) (Figure 5.2). 
The use of immunosuppression in these syngeneic transplants resulted in 
prolongation of transgene expression.
Group C (Immunosuppressed allogeneic): The total number of
positively stained cells was 697.1 ± 517.7 and 827 (32.4-1352) at 1 week,
250.8 ± 104.2 and 224.5 (142.6-386.6) at 4 weeks, 162.5 ± 201.4 and 45.2 (0-
476.4) at 8  weeks and 75.9 ± 141 and 8 . 8  (0-326.8) at 12 weeks (Kruskal-
Wallis, non parametric ANOVA, p>0.05 for all time-points comparisons) 
(Figure 5.3). As with group B, immunosuppression in allogeneic transplants 
resulted in prolongation of transgene expression.
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In group A (non-immunosuppressed syngeneic group), transgene 
expression was virtually undetectable by 4 weeks, whereas in both groups B 
(the immunosuppressed syngeneic) and C (immunosuppressed allogeneic), 
expression of the reporter gene persisted until the termination of the 
experiment at 12 weeks. However, the number of positive staining cells per 
section in both groups decreased substantially with time. There were no 
significant differences in the number of positive staining cells between the 
three groups at 1 week although there was a trend towards more positively 
stained cells in group C (Figure 5.4a). At 4 weeks, transgene expression in 
group C (immunosuppressed allogeneic) was significantly greater than group A 
(non-immunosuppressed syngeneic), (Figure 5.4b) but not group B 
(immunosuppressed syngeneic). At 8  weeks, transgene expression in both 
group B (immunosuppressed syngeneic) and C (immunosuppressed allogeneic) 
was significantly greater than group A (non-immunosuppressed syngeneic), 
(Figure 5.4c). At 12 weeks, there were no significant differences among the 
three groups (Figure 5.4d).
Despite the use of immunosuppression, histological evidence of 
rejection was present in many of the allogeneic animals. At 1 week, 4 animals 
were completely free of rejection while 2  had evidence of moderate grade 
rejection (3A). At 4 weeks, 1 animal had low grade (1 A) and 5 had moderate 
grade (3A) rejection. At 8  weeks, 2 animals had low grade (lA ) and 4 had 
moderate grade (3A) rejection. At 12 weeks, 3 animals had no rejection and 3 
had low grade (lA  to 2 ) rejection. In the non-immunosuppressed syngeneic
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group, 2 animals at 4 weeks, 1 animal at 8  weeks and 2 animals at 12 weeks 
had patchy mononuclear cell infiltrates with rare foci of myocyte damage.
Consistent with the findings in Chapter 3, the cell types that stained 
positively for p-galactosidase included cardiomyocytes, endothelial cells and 
fibroblasts. Smooth muscle cells in the coronary arteries did not stain positive 
for p-galactosidase. As in earlier experiments, the cardiomyocyte was the
predominant transduced cell type. The cell types were determined on the 
basis of morphology by the experienced pathologist. There was no consistent 
pattern of distribution of staining with the exception that staining appeared 
somewhat more accentuated in the subepicardial region.
Discussion
Adenoviral vectors can achieve efficient gene transfer in different 
animal models and in a variety of cell types including non-dividing cells. The 
advantages of these vectors have been previously outlined One of the major 
limitations of these vectors has been the transient nature of transgene 
expression. Previous studies using adenoviral vectors have shown that 
transgene expression is lost or greatly diminished after 30 days This may 
render these vectors unsuitable for gene therapy approaches to chronic 
disorders. However, there may be situations when transient gene expression is 
sufficient to modify the pathological processes. It is also possible that
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immunosuppressive agents may prolong transgene expression^*’ This may 
be of particular relevance in situations, such as heart transplantation, where 
these agents are routinely administered.
This study has demonstrated for the first time that 
immunosuppression prolongs transgene expression in the heart transplant 
setting. Transgene expression was significantly greater at 8  weeks in the 
immunosuppressed syngeneic and allogeneic animals than in the non- 
immunosuppressed animals. At 12 weeks, although there was no statistically 
significant difference in the number of positive staining cells per section 
detected between the 3 groups, transgene expression was still detectable in the 
immunosuppressed groups.
The limited duration of transgene expression after adenoviral-mediated 
gene transfer may be due to immune-mediated mechanisms In support of 
immune mechanism playing a role, prolonged transgene expression has been 
reported in immunologically immature neonatal animals in immunodeficient 
animals and with the use of immunosuppression *^. Furthermore, while 
some authors report the absence of inflammatory infiltrates in the myocardium 
after catheter-mediated delivery of adenoviral vectors to both transplanted and 
non-transplanted h e a r t s ^ d i r e c t  injection has been associated with 
inflammation around the injection site^^’^ ’^^ ^^ . While some of the inflammation 
may be due to the effect of the needle, immune responses to the viral vectors 
may also be responsible. The latter possibility is supported by the results of 
this study. In this study, transgene expression was barely detectable in the
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non-immunosuppressed syngeneic hearts by 4 weeks; but patchy 
lymphocytic infiltrates consistent with myocarditis were noted in 2  of 6  
animals at 4 weeks, 1 of 6  animals at 8  weeks and 2 of 6  animals at 12 weeks. 
These lymphocytic cell types were determined on the basis of cellulai' 
morphology from H & E staining. This may indicate an immune response to 
the vector or transgene even in the absence of detectable transgene expression 
in these animals. Additionally, this study demonstrated that transgene 
expression can be prolonged by immunosuppression with cyclosporine after 
heart transplantation further implying an important role for immunological 
factors . It was noted that there was considerable variability in the number of 
positive staining cells per section in each group of animals. This topographical 
variability in cellular transduction efficiency may be due to unexplained 
biological variability of adenoviral-mediated transgene expression. It may also 
be a result o f the method used in vector delivery in these experiments.
While transgene expression was prolonged to at least 8  weeks with the 
use of cyclosporine, in both the syngeneic and allogeneic immunosuppressed 
groups, there was a significant decline with time despite immunosuppression. 
This may be due to suboptimal dosage of cyclosporine used in the current 
study or non-immune mechanism limiting persistent transgene expression. In 
support of the former hypothesis, rejection was frequently detected by 
histological examination in the allogeneic animals suggesting that the dose of 
immunosuppression used in this study was insufficient to prevent rejection. 
However, there was no correlation between the number of positive staining
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ceils and cellular infiltrate or degree of rejection in any of the 3 groups. In a 
recent study, similar decrease in transgene expression was observed in 
myocardium of athymic rats transduced with an adenoviral vector 
suggesting that non-immune mediated mechanism may also limit the duration 
of transgene expression.
In addition to manipulating the immune response to adenoviral vectors, 
as was done in this study, the problem of transient transgene expression is also 
being addressed by modifications in vector design. Second generation 
adenoviral vectors which have an El a deletion and a temperature sensitive 
mutation in the E2a region have been shown to diminish viral protein 
expression In a mouse modef this has been shown to prolong transgene 
expression in the liver to at least 8  weeks. Recombinant adenoviral vectors 
with all viral genes deleted and which required the use of helper virus for 
propagation have also been generated, but separation of recombinant and 
helper virus remained a problem with the use of these vectors Further 
refinement in vector generation may ultimately lead to a vector system that is 
efficient, non toxic and capable of long term transgene expression.
In conclusion, this study demonstrates that transgene expression using 
adenoviral vectors is prolonged by immunosuppression in the heart 
transplantation setting. The decrease of transgene expression with time is 
probably due to a combination of immune and non-immune mechanisms. This 
study suggests that the routine use of immunosuppression in heart transplant 
setting may prolong transgene expression but the level of expression decreases
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significantly with time. The effect of alternative immunosuppressive regimens 
on transgene expression in the heart transplant setting is worthy of further 
study.
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Figure 5.1: D uration of transgene expression in non-im m unosuppressed
syngeneic heart transplants (G roup A)
Data represents mean number of positively stained cells for (3-galactosidase per
section for each anim al. denotes median value. Viral concentration o f 1 x 10  ^pfu/ml 
was used in all experiments, n = 6  for each time-point. The level o f transgene expression 
dropped significantly after week 1 (Kruskal-Wallis, non parametric ANOVA, p<0.05).
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Figure 5.2: Duration of transgene expression in immunosuppressed 
syngeneic heart transplants (Group B)
Data represents mean number of positively stained cells for p- 
galactosidase per section for each animal. Viral concentration of 1 x 10^ pfu/ml
was used in all experiments, n = 6  for each time-point. denotes median 
value. (Kruskal-Wallis, non parametric ANOVA, p<0.05).
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Figure 5.3: Duration of transgene expression in immunosuppressed 
allogeneic heart transplants (Group C)
Data represents mean number of positively stained cells for |3-
galactosidase per section for each animal. denotes median value. Viral
concentration o f 1  x 1 0  ^pfu/ml was used in all experiments, n = 6  for each 
time-point except week 8  and 12, n = 5. (Kruskal-Wallis, non parametric 
ANOVA, p>0.05).
121
jg
•sSHiIPS. 500-
T ran sg en e  E x p ress io n  a t  1 W eek
J = .
B
Group
Fig 5.4a
ïSIII1I I
400n
300 -
200 .
100 .
T ra n s g e n e  E x p re ss io n  a t  4  W eek s
Group
Fig 5.4b
ïSII!
i i ‘g.
400
300-
200.
100-
T ra n s g e n e  E x p re s s io n  
a t  8 W eek s
B
Group 
Fig 5.4c
200-1
îSHI
g f ^
S  100-
T ra n s g e n e  E x p re s s io n  a t  12  W ee k s
B
Group 
Fig 5.4d
Figure 5.4 a - d: Comparison of level of transgene expression in Group A, B and 
C at 1, 4 ,8  and 12 weeks
Data represents mean ± SD of the number of positively stained cells for p-
galactosidase per section. denotes median value. Asterisk (* )  denotes significant 
differences compared to group A. There was no significant differences between all 
groups at 1 and 12 weeks (Kruskal-Wallis non parametric ANOVA, Dunn's post hoc, 
p>0.05).
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Figure 5.5: Transgene expression by histochemieal staining for beta-
galactosidase at 1, 4, 8 and 12 weeks in all groups
The blue cells are positively stained. Panels A - D demonstrate P-galactosidase 
expression in syngeneic non-immunosuppressed animals at 1, 4, 8 and 12 weeks, 
respectively. Panel E - H demonstrate p-galactosidase expression in syngeneic 
immunosuppressed animals at 1, 4, 8 and 12 weeks, respectively. Panel I - L 
demonstrate p-galactosidase expression in allogeneic immunosuppressed animals at 1,4,  
8 and 12 weeks, respectively. Note that the greatest transgene expression is in the 
immunosuppressed allogeneic animals (panels I - L) and that in all three groups the level 
of expression decreases with time, (x 100)
123
. .V » #
- -  -^•^•••' 4.c^ify ■'- ' ^
■ ,  <> 'W~-' y-C±y 'Ttrcr-
Figure 5.6: Allograft rejection
Evidence of moderate rejection (grade 3A) in allogeneic immunosuppressed 
heart transplant, (x 100)
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Chapter 6 : Distribution and Function of 
Recombinant Endothelial Nitric Oxide Synthase 
in Transplanted Hearts
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Introduction
Introduction of recombinant genes into donor hearts may offer a 
therapeutic intervention that could potentially attenuate the complications of 
heart transplantation including rejection, infection and accelerated transplant 
atherosclerosis. The aetiology and pathogenesis of accelerated transplant 
atherosclerosis appears multi-factorial and non-immune mechanisms including 
early ischaemia-induced endothelial cell injury, ischaemic reperfusion and 
cytomegalovirus infection may all contributed^.
In the cardiovascular system, reduced bioactivity of endothelial nitric 
oxide is a feature of atherosclerosis and vascular injury. Nitric oxide (NO) 
derived from the vascular endothelium regulates vascular tone and inhibits 
proliferation of smooth muscle cells, and adhesion and activation of leukocytes 
and platelets 4 7 ,io6 -io9  Therefore, overexpression of nitric oxide may be 
beneficial in modifying accelerated heart transplant atherosclerosis. Indeed, 
overexpression of iNOS (by gene transfer) attenuates intimai hyperplasia in 
aortic allografts in rats^ d^ .^ However, the role of nitric oxide in a solid organ 
such as the heart is complex. Under physiological conditions, basal release of 
nitric oxide in the heart is important in preserving ventricular function'd^. In 
contrast, excessive production of NO, secondary to activation of the inducible 
form of nitric oxide synthase (iNOS), which occurs in conditions such as 
allograft r e j e c t i o n '"  and endotoxaemia reduces myocardial contractility"^""''.
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The initial experiments in this thesis established the feasibility of 
adenoviral-mediated gene transfer in the transplanted heart using a reporter 
gene. In order for adenoviral-mediated gene transfer to be a useful tool for 
studying the pathogenesis of the processes affecting transplanted hearts, the 
feasibility of overexpressing biologically relevant and important genes need to 
be addressed. Therefore, experiments were designed to determine the 
distribution and functional consequences of overexpressing endothelial nitric 
oxide synthase (eNOS) gene in the transplanted heart.
Methods
Construction, Propagation and Purification of Adenoviral Vector
A recombinant adenovirus containing the cDNA encoding eNOS was 
generated as described in Chapter 2. Briefly, bovine eNOS cDNA was cloned 
into the shuttle plasmid pACCMVpLpA. The resulting plasmid was 
linearised with Nrul and cotransfected with dl309 into 293 cells by calcium 
phosphate/DNA coprecipitation. dl309 is a biologically selected, restriction 
enzyme-site-loss variant of wild type adenovirus type 5 which retains only a 
single Xbal site at nucleotide 1339. 293 cells are human embryonic kidney 
carcinoma cells which have been transformed with the left end of human 
adenovirus type 5 DNA. Recombinant adenoviral vectors were generated by
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homologous recombination. The adenoviral vector encoding for the reporter 
gene p-galactosidase (AdLacZ) was used in all experiments as control.
Animals, Operation and Gene Transfer
Inbred male Lewis (RT-1^) rats (250 to 300 grams) were used as donors 
and recipients.
Heterotopic abdominal heart transplantation using standard 
microsurgical techniques was performed as previously described. For gene 
transfer, either adenoviral vector carrying the eNOS or the LacZ (control) gene
9at a concentration of 1 x 10 pfu/ml (total volume 350 pi) was infused over 5 
seconds into the coronary arteries via the aortic root. The pulmonary artery 
was clamped during viral infusion and the viral solution was not flushed out at 
the end of 60 minutes cold storage prior to performing heart transplantation. 
Viability of the grafts was verified daily by palpation of the beating 
transplanted heart.
Tissue Analysis
Transplanted hearts (n = 12 per group) were harvested 4 days after 
surgery. For PCR, RT-PCR, immunohistochemical staining and NOS activity 
assay, hearts (n = 6  per group except PCR for control, n=2.) were flushed with 
Phosphate-buffered saline solution and then cut into apical, mid ventricular
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and basal sections. For assessment of ventricular function transplanted hearts 
(n = 6  per group) were removed and prepared for Langendorff perfusion.
Polymerase Chain Reaction (PCR)
The presence of recombinant eNOS DNA from the transduced hearts 
was analysed by PCR. Genomic DNA was prepared from apical and basal 
segments of eNOS (n=6 ) and LacZ transduced hearts, (n=2 as control) by 
standard proteinase K digestion in phenol and chloroform extraction 
conditions. Primer sequences utilised for the experiments were as follows: 
upper 5' AGO CGT CGG TGG GAG GTC TAT, lower 5' GCG CAC AGA 
GTG TCG TAG GTG ATG. The upper primer was complementary to the 
CMV promoter. PCR components include: 1 x PCR buffer (Promega, 
Madison, WI), 1.5 mM MgCl^, 200 uM of dNTP mix, 0.5M dimethyl 
sulfoxide (DMSO), 0.1 jiM of each primer, and 2.5 units Taq DNA 
polymerase (Promega, Madison, WI). One microgram of DNA was amplified 
using 35 PCR cycles (94°C for 30 seconds,dénaturation; 63°C for 30 seconds, 
annealing; and 72°C for 30 seconds, polymerisation). The PCR product 
amplified was 356 base pairs in length.
Reverse Transcriptase PCR (RT-PCR)
Expression of recombinant eNOS mRNA was detected by reverse 
transcriptase PCR. Total RNA was prepared from apical and basal segments
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of transplanted hearts using RNA STAT-60 isolation reagent (Tel-Test “B”, 
Friendswood, TX). Reverse transcription (RT) was performed using a 
Superscript Preamplification System for First Strand cDNA Synthase Kit 
(Life Technologies Inc., Gaithersburg, MD). Total RNA was transcribed into 
cDNA using oligo(dT) and random hexamers priming methods according to the 
manufacturer’s protocol. RT-generated cDNA encoding for the eNOS gene 
was amplified using 35 PCR cycles (94°C for 45 seconds, 60^C for 45 seconds 
and 12^C for 60 seconds). Sequences utilised for the experiments were as 
follow: upper 5' TCAACCAGTACTACAGCTCC, lower 5'
GTGGTTGCAGATGTAGGTGA. These primers were derived from bovine 
eNOS sequence and they do not generate PCR product with endogenous rat 
eNOS. Primers designed to detect expression of Glyceraldehyde 3-Phosphate 
Dehydrogenase (G3PDH, Amplimer set, Clontech Laboratories, Inc., Palo 
Alto, CA) were used to test the efficiency of cDNA synthesis. The PCR 
product for eNOS migrated to 250 base pairs and the G3PDH at 450 base 
pairs.
Immunohistochemical staining
Midventricular cross sections of the transplanted hearts were 
embedded in OCT medium (Miles, Elkhart, Ind.) and snap frozen in a liquid 
nitrogen-cooled isopentane bath. Sections (5 pm thick) were cut at 25pm 
intervals, fixed for 10 minutes in cold acetone (4°C), fan-dried for 10 minutes
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and further fixed in 1% paraformaldehyde/EDTA for 3 minutes. Endogenous 
peroxidase activity was blocked with 0.1 % sodium azide/0.3% H^O  ^ for 10 
minutes. Incubating sections with 5% goat serum/PBS-Tween 20 blocked non­
specific protein binding sites. Then 5 pg/ml of anti-eNOS monoclonal 
antibody (N30020) (Transduction Laboratories, Lexington, KY) was added 
incubated for 60 minutes at room temperature. After rinsing, biotinylated 
rabbit anti-mouse F(ab')2 (1:300) was added for 20 minutes. After fiirther 
incubation for 20 minutes with peroxidase conjugated-streptavidin (1:300), the 
slides were incubated for 30 seconds in 0.1 M sodium acetate buffer, pH 5.2. 
Then the slides were placed in AEC (3-amino-9-ethyIcarbazole) substrate 
solution and incubated for 15 minutes at room temperature, counterstained in 
mercury-free haematoxylin for 1 minute and further rinsed for 3 minutes in 
cold running tap water before being mounted. Myocardial cells with 
immunoreactivity were then counted from all 5 sections of both control (LacZ) 
and experimental (eNOS) groups and a mean calculated for each heart.
Nitric Oxide Synthase Activity
NOS activities of LacZ (as control) and eNOS transduced hearts were 
determined by measuring the conversion of L-[^H]-arginine to L-[^H]-citrulline 
by methods originally described by Myatt"^ and modified by Barber"^.
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Immediately after harvesting transplanted hearts, mid-ventriculai- 
sections were minced with surgical scissors and frozen at -70 °C until the time 
of assay (<30 days). For activity assay, the frozen tissue was diluted in 5 
volumes of ice cold homogenisation buffer of the following composition: 50 
mM Tris, 320 mM sucrose, 0.1 mM EDTA, 100 pg/ml 
phenylmethylsulfonyl, plus one tablet Complete'*'^ (Boehringer Mannheim, 
Indianapolis, IN) protease inhibitor cocktail per 50 ml buffer, pH 7.8. 
Samples were homogenised on ice for 10 sec at full speed using a Tekmar 
tissue homogenizer (Tekmar, Cincinnati, OH). Homogenates were centrifuged 
at 2000 X g for 15 min at 4°C to remove cellular debris. The supernatant was 
passed onto an equilibrated 10-DG desalting column (Bio-Rad, Hercules, CA) 
and eluted according to the manufactures directions. A small aliquot was used 
to determine protein concentrations using bicinchoninic acid protein assay 
reagent (Pierce, Rockford, IL). Protein homogenates were used immediately 
for determination of NOS activity.
To quantitate NOS activity, duplicate reactions were carried out in the 
presence of calcium (total activity), in the absence of calcium plus EGTA 
(calcium independent activity), and in the absence of calcium plus EGTA in 
the presence of N^-monomethyl-l-arginine (L-NMMA) (non-specific 
activity). Reactions were started by adding 150 pi of protein homogenate to 
150 pi of a cofactor mix such that final concentrations were as follows: 14.7 
nM ^H-l-arginine (0.3 pCi specific activity at 6 8  Ci/mmol), 5 pM 1-arginine, 54 
mM 1-valine, 1.2 mM MgCU, 1 mM NADPH, 50 U/ml calmodulin, 2 pM
132
FAD, 10 pM tetrahydrobiopterin, and, as described above, with or without 
0.83 mM CaCl2 , 1 mM EGTA, and 2 mM L-NMMA. The reaction was 
incubated on a shaker at 27 °C for 1 hr and terminated by the addition of 1.5 
mis ice cold stop buffer (20 mM HEPES, 8  mM EDTA, pH 5.5). Separation 
of ^H-l-arginine from ^H-l-citrulline was accomplished using affinity columns 
containing a resin which retains the charged species of ^H-l-arginine while 
allowing ^H-l-citrulline to pass through. Thus the assay mixture was passed 
over Poly-Prep chromatography columns (Bio-Rad) loaded with 1 ml of 
equilibrated AG 50W-X8 Na^ form 200-400 mesh molecular biology grade 
resin (Bio-Rad) and the elute collected into 18 mis of Opti-Fluor (Packard, 
Meriden, CT). The column was washed with 2 mis of water while continuing 
to collect into the scintillation fluid. ^H-l-citrulline activity was determined 
using a Beckman 6800 liquid scintillation counter. Activity calculations 
account for scintillation counting efficiency and the ratio of ^H-l-arginine to 
non-radioactive 1-arginine in the incubation mixture. Nitric oxide produced by 
NOS is presumably in a 1:1 molar ratio with 1-citrulline and thus NOS activity 
is expressed as pmoles of ^ H-l-citrulline produced per mg of protein per hour. 
Calcium dependent activity equaled total activity minus calcium independent 
activity after correcting for non-specific activity.
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Assessment of Left Ventricular Function
Functional effects of eNOS transduction on transplanted hearts were 
determined using the Langendorff preparation (Langendorff, 1895) (Figure 
2.7). The set-up for Langendorff preparation was described in Chapter 2. 
Briefly, explanted eNOS and LacZ transduced hearts were arrested with cold 
saline, quickly excised and then mounted on the Langendorff apparatus and 
perfused immediately with Krebs buffer. Left ventricular function was 
expressed as left ventricular developed pressure (LYDP = left ventricular 
systolic pressure minus left ventricular diastolic pressure). Left ventricular 
function curves were constructed by progressively increasing the volume of 
the balloon to achieve end-diastolic pressures (LYEDP) of 0, 4, 8 , 12, 16 and 
20 mmHg. Following the assessment of cardiac function, the LYDP was 
maintained at the optimal level and the heart was allowed to stabilise for 5 
minutes. Coronary flow was measured at 1, 2, 3, 4, 5, 10, 15, 20, and 25 
minutes after beginning a continuous infusion of N^-Monomethyl-L-Arginine, 
lO 'd M (L-NMMA). L-NMMA is an inhibitor of nitric oxide synthase. All 
data were collected and analysed.
Statistical Analysis
The quantitative data of number of cells stained positive for eNOS was 
expressed in median and range because of unequal variances. The data for NOS 
activity assay and functional studies suggested equal variances. Therefore,
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results of NOS activity (picomoles/mg protein/hrs) were expressed as mean ± 
SEM; n represented the number of animals. NOS activity (picomoles/mg 
protein/hrs) of AdeNOS transduced hearts were compared against control 
(AdLacZ transduced) using a two-tailed Student’s t-test for unpaired data. 
For analysis of left ventricular function, areas under the curves were compared 
by analysis of variance. Analysis of variance for repeated measurements was 
used to analyse changes in coronary flow. For post hoc analysis, Bonferroni 
correction was used when a significant F value was found. A P value less than 
0.05 was considered significant.
Results
PCR
To confirm gene transfer, PCR was performed on DNA extracted from 
AdeNOS and AdLacZ transduced hearts. Bands at 356 base pairs 
corresponding to positive control for bovine eNOS were present in all lanes for 
AdeNOS transduced hearts (n=6 ). In contrast, no bands were seen in the 
controls (AdLacZ transduced hearts, n=2; Figure 6.1). The PCR product was 
subsequently sequenced by Dr O’Brien’s group and determined to be bovine 
eNOS.
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RT-PCR
To confirm transcription of the recombinant eNOS gene, transduced 
hearts were examined for the presence of eNOS mRNA by RT-PCR. Bands at 
250 base-pairs corresponding to positive control for mRNA for eNOS were 
present in all lanes for eNOS transduced (n==6 ) but not in the AdLacZ 
transduced hearts (n=6 , Figure 6.2). The reaction was negative in the absence 
of reverse transcriptase.
PCR and RT-PCR confirmed the presence of recombinant eNOS in the 
AdeNOS transduced hearts. As both these techniques were non-quantitative, 
the level of transgene expression was determined by NOS activity assay.
Immunohistochemical Staining
The presence of eNOS was detected by immunohistochemical staining. 
As the antibody to eNOS used was not specific for recombinant eNOS, 
endothelial cells in both the AdeNOS and the AdLacZ (control) groups were 
immunoreactive for eNOS. In the AdLacZ transduced hearts (control), the 
mean number of immunoreactive cardiomyocytes per section was 2  ± 1 (mean
± SE, Figure 6.3). In the AdeNOS transduced hearts, the mean number of 
immunoreactive cardiomyocytes per section was 254 ± 102 (mean ± SE, 
Figure 6.3). The majority of the eNOS positive staining was found in the 
endothelial cells of the capillaries in the AdLaZ group. The number of positive 
eNOS staining cardiomyocytes was significantly greater in the AdeNOS hearts
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compai'ed to AdLaZ hearts. This finding suggested that transgene expression 
may have eontributed to the greater number of eNOS staining cardiomyocytes 
in the AdeNOS group.
NOS Activity
Total NOS activity was 41.7 ± 5.1 pmoles L-pH]-citrulline/mg 
protein/hr in the AdLacZ transduced (control) group and 57.7 ±5 .2  pmoles/mg 
protein/hi* in the AdeNOS transduced group, (n= 6  per group, P=0.05) (Figure 
6.4). Calcium-dependent activity of NOS was 38.4 ± 4.7 pmoles/mg 
protein/hr in the AdLacZ transduced group vs 53 ± 5 pmoles/mg protein/hr in 
the eNOS transduced group (P = 0.05). Calcium-independent activity of NOS 
was 3.3 ± 0.5 pmoles/mg protein/hr in the AdLacZ transduced group and 4.7 ±
1.5 pmoles/mg protein/hr in the AdeNOS transduced group (P = NS).
Although the activity assay could not separate endogenous from 
recombinant eNOS, the results showed that calcium dependent activity of 
NOS was greater in the AdeNOS group compared to the AdLaZ group . This 
suggested that the increased in NOS activity in the AdeNOS was contributed 
by the overexpression of the eNOS transgene.
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Cardiac functional assessment
Mean coronary flow after the initial period of stabilisation was 11.7 +
0.5 ml/min in the AdLacZ group and 10.9 ± 0.7 ml/min in the AdeNOS group.
There were no significant differences in cardiac function as measured by LVDP 
(left ventricular developed pressure) between the two groups (n= 6  per group, 
Figure 6.5).
L-NMMA affected coronary flow comparably in both groups (Figure 
6 .6 ). During the initial period of L-NMMA inftision, coronary flow in all 
hearts increased transiently, but then decreased by 25 percent of baseline flow 
within two minutes.
Discussion
The aim of the present study was to demonstrate the feasibility and 
ftmctional consequences of overexpressing eNOS in the transplanted heart 
using adenoviral-mediated gene transfer. Successful gene transfer and transgene 
expression in the transplanted heart was confirmed by PCR and RT-PCR. 
The significantly greater number of eNOS positive staining cardiomyocytes in 
the AdeNOS compared to the AdLaZ (control) group suggested the presence 
of recombinant eNOS in the former. This was further supported by the 
increased NOS activity in the AdeNOS group. The limitation of the 
immunostaining and activity assay was the inability to exclude the possibility
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of induced endogenous eNOS expression. Recombinant gene expression 
however, did not affect ventricular function or coronary flow as assessed using 
a Langendorff preparation follovwng heterotopic heart transplantation (non­
loaded left ventricular chamber).
This study demonstrated the feasibility of using adenoviral vectors for 
gene transfer of a biologically relevant molecule to the transplanted heart. 
Adenoviral-mediated gene transfer was used because it has been shown to 
efficiently transduce non-replicative cells. Chapters 3 and 5 suggested that in 
the transplant setting, some of the limitations of this technology including the 
transient nature of transgene expression"^ and the difficulty of achieving 
prolonged luminal contact of vector in coronary vessels may be partially 
overcome. In this study as in Chapters 3 and 5, transgene expression was seen 
predominantly in cardiomyocytes. Interestingly, eNOS was also detected in 
small numbers of ventricular myocytes of AdLacZ transduced hearts. This 
observation is consistent with previous studies showing the presence of 
eNOS in cardiomyocytes.
The potential effect of nitric oxide (NO) on myocardial function has 
been the subject of many studies with conflicting conclusions. The excessive 
and prolonged production of NO by inducible nitric oxide synthase (iNOS) in 
transplantation rejection and sepsis may be responsible for the negative 
inotropic effect on cardiac m uscles'"’"^’"'*. In contrast, other studies on 
isolated heart preparations showed that increasing NO using NO donors 
resulted in enhanced cardiac contractility'^ ' and supplementation of NO during
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the period of ischaemia-reperfusion has also been shown to have beneficial 
effects'^^"^^. Furthermore, cardiac preservation in the heterotopic heart 
transplant model was enhanced by supplementation of the nitric oxide 
pathway'^"'. In a recent study, the importance of basal NO production in 
preserving myocardial systolic function and coronary vascular tone was 
demonstrated"''. Therefore, the role of eNOS in cardiomyocyte is unclear. To 
address this issue, we studied the effect of overexpression of eNOS on the 
contractility and coronary flow of the transplanted heart in a model in which 
eNOS overexpression was predominantly in cardiomyocytes. Using the 
Langendorff model, despite documented eNOS overexpression, this study did 
not show any significant difference in contractility and coronary flow between 
the eNOS and the LacZ transduced hearts. This negative result may suggest 
that eNOS is not involved in regulating cardiac contractility and coronary 
blood flow or that the distribution or efficiency of transgene expression was 
inadequate to affect these variables. If the latter possibility is true, more 
efficient means of transferring genes to the myocardium in the transplantation 
setting may affect cardiac contractility and coronary blood flow.
It has been proposed that eNOS gene transfer to the donor heart may 
be useful in the treatment or prevention of transplant-related atherosclerosis. 
This condition is the greatest limitation to long-term survival after heart 
transplantation and there is currently no effective treatment except re­
transplantation. Endothelial nitric oxide is an important modulator of vascular 
smooth muscle tone and proliferation. Potential beneficial properties of nitric
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oxide include inhibition of platelet aggregation, leukocyte adhesion and smooth 
muscle cells proliferation"'®’"' .^ As smooth muscle cell proliferation forms an 
integral part of the pathologic process of accelerated transplant 
atherosclerosis,® overexpression of eNOS by adenoviral-mediated gene transfer 
leading to a controlled release of NO at the target area may modify this 
p r o c e s s w i t h o u t  compromising cardiac function and avoiding systemic 
effects. In this model, however, transgene expression was mainly detected in 
cardiomyocytes. In contrast, rare endothelial cells expressed the transgene. 
Therefore, it remains to be seen whether this pattern of overexpression of 
eNOS will influence intimai processes such as smooth muscle cell hyperplasia. 
However, NO is diffusible and the laboratory of Dr O'Brien has previously 
shown that adventitial expression of eNOS in the rabbit carotid artery or the 
canine basilar artery can effect vascular reactivity"'®’'^ ®. This suggests that 
eNOS overexpression outside the intima (e.g. in cardiomyocytes surrounding 
small vessels) may influence pathological processes involving the intima.
In summary, delivery of genes to the transplanted heart via the aortic 
root targets cardiomyocytes. This study demonstrated successful gene 
transfer of eNOS to the transplanted heart using PCR and RT-PCR. 
Immunohistochemistry and measurement of NOS activity suggested 
overexpression of eNOS Transgene in AdeNOS transduced hearts compared to 
controls. eNOS overexpression in cardiomyocytes in this model did not result 
in alteration of myocardial contractility or coronary blood flow. In the future, 
methods that enhance gene transfer efficiency may prove useful to modify
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these variables in the donor organ. Whether or not transduction of 
cardiomyocytes will modify vascular consequences of transplantation remains 
to be determined.
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Figure 6.1: PCR to detect recombinant cDNA
PCR analysis to detect recombinant eNOS gene in AdeNOS and 
AdLacZ (control) transduced hearts using primers specific to the recombinant 
eNOS. Lane 1 is the reference ladder for number of base pairs. Lane 2 is the 
positive control (eNOS plasmid). Lanes 3 and 4 are negative controls. Lanes 5 
and 6  represent AdLacZ transduced hearts (n=2, control). Lanes 7,8,9,10,11 
and 12 represent AdeNOS transduced hearts(n=6 ). Positive bands confirming 
the presence of recombinant eNOS gene cDNA were observed only in Lanes 7 
- 12.
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Figure 6.2: RT-PCR to detect recombinant mRNA
RT-PCR analysis to detect mRNA for recombinant eNOS in AdeNOS 
and AdLacZ (control) transduced hearts. Lane 1 represents the 100 base pairs 
DNA marker. Lane 2 represents positive signal at 250 base pairs in cDNA 
derived from plasmid with eNOS gene. Lane 3 represents positive signal at 
450 base pairs for positive control (PCR product of Glyceraldehyde 3- 
Phosphate Dehydrogenase). Lane 4 represents negative signal at 661 base 
pairs in cDNA derived from plasmid with inducible NOS (iNOS). Lane 5 = 
water. Lane 6  to 11 = controls (n=6 , LacZ transduced hearts) showing no 
signal for eNOS mRNA. Lane 12 to 17 = eNOS transduced hearts (n=6 ) 
showing positive signals for eNOS mRNA. These primers were derived from 
bovine eNOS sequence and they do not generate PCR product with 
endogenous eNOS.
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Figure 6.3: Immunohistochemical staining of AdLacZ transduced hearts
Immunohistochemical staining of 5 pm section of the midventricular 
section of AdLacZ transduced heart using monoclonal antibody to eNOS. 
Arrows mark positive staining (brown) in the endothelial surfaces of vessels 
including capillaries.
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iFigure 6.4: Immunohistochemical staining of AdeNOS transduced 
hearts
Immunohistochemical staining of 5pm section of the midventricular 
section of AdeNOS transduced heart using monoclonal antibody to eNOS. 
Small arrows mark positive staining (brown) in the endothelial surfaces of 
vessels including capillaries and cardiomyocytes. There is an area of organising 
ischaemia in the lower right-hand comer (large arrow).
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Figure 6,5: NOS activity assay
NOS activity of AdLacZ and AdeNOS transduced hearts deterniined by 
measuring the conversion of L“[^H]-arginine to L-[^H]-citrulline, expressed as mean ± 
SEM in pmoles/mg protein/hr (n= 6  in each group). The AdeNOS transduced hearts 
showed greater level of total and calcium-dependent NOS activity compared to 
AdLacZ transduced hearts, (two-tailed Student's t- test, P = 0.05). Calcium- 
independent NOS activity was similar in both groups.
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Figure 6.6: Assessment of left ventricular function in transduced hearts
Four days after gene transfer and transplantation, AdeNOS and 
AdLacZ transduced hearts were explanted and left ventricular function 
assessed by Langendorff preparation. Left ventricular function was expressed 
as LVDP mmHg (left ventricular developed pressure, mean ± SEM. No 
significant difference in LVDP was detected between AdLacZ and AdeNOS 
transduced hearts (n= 6  per group).
148
%change in flow: LacZ
25-,I %change in flow: eNOSOHi
h
g* -25I
-50 30
Time in m ins
Figure 6.7: Assessment of coronary flow in transduced hearts
Four days after gene transfer and transplantation, AdeNOS and 
AdLacZ transduced hearts were explanted and coronary flow was assessed 
using an in-flow meter in the Langendorff preparation. Changes in coronary 
arterial flow following L-NMMA infusion (10*  ^mmol) were recorded. Results 
were expressed as mean ± SEM % change in flow (ml/min, n= 6  per group) 
from baseline flow rate (before L-NMMA infusion). Infusion of L-NMMA 
caused comparable changes in coronary blood flow in AdLacZ and AdeNOS 
transduced hearts.
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Chapter? : Conclusions
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Summary and Future Directions
This thesis addressed many of the basic issues in adenoviral-mediated 
gene transfer to the transplanted heart. The potential for gene transfer in the 
heart transplant setting is exciting. If this technique is successful, then it may 
prove to be an extremely valuable tool in the study of the biology of heart 
transplantation. With better understanding of the pathogenesis of the disease 
processes, strategies for therapeutics could be realised.
In Chapter 1, a brief introduction to heart transplantation and the 
challenges faced were discussed. The various vector systems for gene transfer 
were described and the advantages and disadvantages of these vectors 
discussed. The most efficient vectors to date for gene transfer are the 
adenoviral vectors. They can transduce non-replicative cells and are thus 
ideally suited as vectors for the heart.
Chapter 2 defined the aims of the study. The animal model used and 
the technical training were described. The biosafety concerns of adenoviral 
vectors with emphasis on precautions for working with these agents were also 
discussed. This would be a significant issue in clinical trials.
Chapter 3 and 4 studied the feasibility of transferring genes to the 
transplanted hearts and examined the conditions that may favour efficient gene 
transfer. When this study was initiated, very little was known of gene transfer 
in the transplanted heart. The results suggested the importance of coronary
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distension during viral administration on the efficiency of gene transfer. The 
role of distending pressure in facilitating cardiovascular gene transfer has also 
been shown in other studies of gene transfer to the vasculature^*’^ ^^ . A method 
of vector delivery which resulted in relative efficiency of gene transfer was 
established in this chapter which facilitated subsequent studies. Also it was 
noted that there were considerable inter-animal variability in the results. This 
may be due to the biological variability of gene transfer or a reflection of the 
method of vector delivery. If it is the latter, then alternative techniques of 
vector delivery, for example recirculating infusion of the vector, should be 
explored.
A major limitation in adenoviral-mediated gene transfer is the transient 
nature of transgene expression. In addition, the effectiveness of a second 
administration is curtailed with the formation of neutralising antibodies. This 
may limit the usefulness of adenoviral vectors in treating chronic diseases. 
Chapter 5 investigated the effects of immunosuppression, which is routinely 
used in clinical transplantation to prevent rejection, on duration of gene 
transfer in both syngeneic and allogeneic transplant models. It showed a 
moderate prolongation of transgene expression. Whether this moderate 
prolongation of duration of transgene expression is adequate for modifying 
disease processes affecting transplanted hearts warrants further investigation.
In Chapter 6 , the feasibility of transferring an important biological gene 
to the transplanted heart was confirmed. The limitation of the study in 
Chapter 6  was the lack of distinction between endogenous eNOS expression
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which may be upregulated and the overexpression of eNOS by the 
recombinant eNOS transgene. However, the data presented was supportive of 
the eNOS transgene being overexpressed in the studied hearts. The effects of 
overexpressing nitric oxide synthase on these hearts were studied. Nitric oxide 
has a number of beneficial properties, including inhibition of smooth muscle 
cell proliferation, that may modify the pathogenesis of accelerated transplant 
atherosclerosis. This warrants further investigation in an experimental model 
of heart transplant atherosclerosis.
In conclusion, gene transfer to the transplanted heart is feasible. The 
success of gene transfer is dependent on the efficiency of the delivery vectors. 
An ideal vector would efficiently deliver genes to the appropriate cell type, result 
in long-lived regulated transgene e)q)cession and avoid toxicity. The current 
vectors fall far short of these goals. Further devdopment and advances in vector 
design may help fulfil these requirements. Therefore, with the ideal vector 
transferring a therapeutic gene to an appropriate targpt cell type or organ, gene 
therapy may favourably modulate immune responses and enhances graft function 
in clinical heart transplantation.
The Current Status Of Human Gene Therapy:
Human gene therapy has been heralded for its potential to revolutionise 
modern medicine th rou^  the use of recombinant DNA technology to treat
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inherited and acquired diseases. The first human gene therapy clinical trial^  ^was 
performed on two girls with inherited adenosine deaminase deficiency (ADA) in 
1990. A lthou^ the results of this trial were difficult to interpret, due a lack of 
controls and the patients continued recdving standard therapy, the observations 
were consistent with the conclusion that this strategy of ex vivo gene transfer 
evoked biological responses that were relevant to the treatment of ADA 
deficiency. Since then, the number of clhncal protocols world wide have 
increased dramatically. By 1996, there were at least 232 p ro toco lsapp roved  
for clinical trials. The majority of the trials involves inherited diseases (induding 
cystic fibrosis), cancer and infectious diseases. Recently, a clinical gene therapy 
trial of the heart was initiated^^^. A naked plasmid DNA encoding for the 
vascular endothelial growth factor (VEGF) gene was directly injected into 
ischaemic areas of the myocardium to stimulate angiogenesis. Earl^ results were 
encouraging
However, the initial enthusiasm surrounding the potential role of gene 
therapy in the treatment of human disease has now been tempered by the 
realism of the current situation. Significant obstacles to success include the 
inconsistency of results, vector production and the lack of an ideal vector^^^.
The potential applications of human gene transfer are broad due the 
wide variety of diseases. The ideal vector will likely to be different for each 
application. Clinical experience to date suggests that adenovirus, retrovirus 
and plasmid-liposome vectors all require further refinement. Recently, new
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generation of adenoviral vectors are becoming available. These vectors have 
less viral sequence and are therefore less toxic and results in more prolonged 
transgene expression. Therefore, the future for human gene therapy remains 
promising.
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